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Abstract 
 
Hypertension is a chronic, often asymptomatic, and highly prevalent 
cardiovascular disorder. Medications prescribed to lower blood pressure in hypertensive 
individuals are successful but are not without side effects or associated costs that render 
these agents inconvenient to patients. Furthermore, from a public health standpoint, a 
proactive approach to preventing or delaying progression into a hypertensive state in at-
risk individuals is promising. Researchers have discovered bioactivity in peptides derived 
from food protein sources and the observed potential for blood pressure lowering effects 
through ACE inhibition has fueled further interest.  This thesis focuses on the potential 
use of dairy- and soy- derived bioactive peptides in lowering blood pressure through 
ACE inhibition. Chapter 1 provides an overview of hypertension, including its 
prevalence, clinical definition, associated risk factors, and potential contributors to its 
complex pathophysiology, as well as current medications and a brief introduction to the 
use of bioactive peptides in a functional food.  Chapter 2 presents a systematic review of 
the literature, with a strong emphasis on in vivo animal and human studies regarding the 
blood pressure lowering potential of dairy- and soy- derived bioactive peptides. Chapter 3 
shares the findings of our study on the acute effects of whey- and soy- derived bioactive 
peptides administered in the form of a cookie to overweight, pre-hypertensive men and 
postmenopausal women. Finally, this thesis is concluded with a brief summary provided 
in Chapter 4. 
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Hypertension 
Prevalence  
Affecting 33% of Americans1 and approximately 1 billion people worldwide2, 
hypertension is considered to be the most prevalent of cardiovascular disorders and a 
significant public health concern3.  It has been projected that by the year 2025, 
approximately 29% (1.56 billion) of the world’s population will be hypertensive, 
particularly in both economically developed and developing countries2. 
Disparities in prevalence exist among races, levels of socioeconomic status, age, 
and between genders.  In the U.S., approximately 43% of African Americans are affected 
by hypertension compared with both White and Hispanic Americans1.  Such prevalence 
within this group is considered to be one of the highest world-wide4.  Compared with 
their White and Hispanic American counterparts African Americans are more likely 
aware of their hypertensive state, yet they are less successful in achieving target blood 
pressure levels with treatment1.  Differences within Hispanic American groups have been 
observed as well, with Puerto Rican and Dominican Americans having the highest rates 
of hypertension and Cuban Americans having the lowest5.  In the 2005-2008 National 
Health and Nutrition Examination Survey, estimates of the prevalence of hypertension 
among races were reported to be 40% and 43%, 24.6% and 25%, and 30.5% and 28% for 
African American men and women, Mexican American men and women, and White 
American men and women, respectively4.  Within Asian American groups, both Filipino 
and Japanese Americans were reportedly more likely to be diagnosed with hypertension 
(27% and 25%, respectively) compared to Chinese (17%) and Koreans (17%)6.  Low 
socioeconomic status has been associated with hypertension for reasons that may include 
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occupational stresses and working conditions and having low birth weight, although the 
association between maternal malnutrition and hypertension later in life is ambiguous7.  
However, several studies support a fetal programming hypothesis, contending that 
vitiation of the intrauterine environment (presumably a consequence of maternal 
malnutrition) results in suboptimal growth that may predestine the fetus to cardiovascular 
complications later in life8.  In contrast, those with higher socioeconomic status tend to be 
better educated in the prevention of hypertension and are more likely to follow 
medical/pharmacological interventions7  
Although hypertension is growing alongside the rise in obesity rates among youth 
populations, it is more common among adults and increases with age with more than 50% 
of the US adult population identified as hypertensive1.  The prevalence of hypertension is 
typically higher in men than women until the age of 45.  Between 45 and 64 years of age, 
men and women have similar rates of hypertension, and beyond 64 years of age, 
hypertension is more prevalent in women4. 
 
Definition 
Sometimes referred to as ‘the silent killer,’ hypertension is a chronic, often 
asymptomatic disorder autonomously correlated with cardiovascular disease risk.  
Specifically, hypertension imposes greater risk for myocardial infarction (MI), heart 
failure, and stroke3, and is a leading cause of kidney failure1.  
Hypertension is clinically defined as having either a systolic pressure of 140 
mmHg or higher, a diastolic pressure of 90 mmHg or higher, or both.  Many individuals 
are at an increased risk for hypertension, with either systolic pressures ranging from 120-
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130, diastolic pressures of 80–89, or both.  These ranges define prehypertension and such 
individuals are at high risk for developing hypertension1.   Hypertension can be 
categorized as Stage I or Stage II, depending on its severity.  Stage II is defined as a 
systolic pressure of 160 mmHg or higher or a diastolic pressure of 100 mm Hg or higher, 
or both.  
Hypertension can be classified as essential (primary) or secondary. Essential 
hypertension includes all cases in which the origin is unidentified and accounts for 85-
90% of all hypertension diagnoses9,10. While origination is unclear, it is almost 
unanimously agreed upon that essential hypertension is multifactorial and ensues from a 
complexity of interactions, beginning at the genetic level8,9,11-13. It has been estimated 
that, on average, 30-60% of the variation in blood pressure between individuals, after 
age- and sex- adjustments, results from genetic contributions, including gene 
polymorphisms. It is currently believed to be under polygenic influence in which the 
effects of multiple genes ultimately characterize susceptibility11.  It is imperative to 
acknowledge the essential contributions of environmental factors that reportedly account 
for 20% of the observed variations in blood pressure between individuals.  While each 
gene variant may individually offer a small effect on overall blood pressure, together 
these may result in considerable blood pressure elevation when influenced by certain 
environmental factors11. These factors will be described in subsequent sections.  The 
primary abnormality observed in essential hypertension is increased peripheral resistance 
resulting from vascular changes that include thickening of the arterial walls and 
abnormalities in vascular tone12,14. 
 5 
It is suggested that approximately 10-15% of individuals have secondary 
hypertension, so-named because they have another condition that has been identified as 
the cause.  Common causes of secondary hypertension include renal parenchymal 
disease, renal artery stenosis due to either atherosclerosis or fibromuscular dysplasia 
(more common in children and young adults), and primary aldosteronism (leading to 
increased salt and water retention and potassium losses, in response to increased 
aldosterone).  Other identified causes include Phaeochromocytoma and Paraganglioma 
(tumors in the adrenal medulla and in or outside the sympathetic and parasympathetic 
paraganglia, respectively) and Cushing’s Syndrome (marked by significantly high 
secretions of glucocorticoids)9. 
 
Risk factors 
Risk factors for the development of essential hypertension include, as previously 
described, age, race, and ethnicity.  Older age is associated with higher risk for 
hypertension in most populations.  African Americans are more likely to develop 
hypertension earlier in life, with greater severity, and to have higher rates of 
hypertension-related health complications1.  Both overweight and obese individuals (as 
defined by body mass indexes (BMI) of 25.0 to 29.9 and 30 or higher, respectively) have 
increased risk for hypertension.  The obesity epidemic that now spans across all age 
groups is largely accountable for the increased prevalence of hypertension now observed 
in youth less than 18 years of age.  It has been suggested that risk factors for 
cardiovascular disease present in youth are strong predictors of early manifestations of 
atherosclerosis in adulthood and, similarly, blood pressure in childhood is considered a 
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significant predictor of blood pressure in adulthood15.  There are a number of lifestyle 
factors that can increase the risk of hypertension including smoking, alcohol, and 
television viewing.  
In terms of diet, frequent high sodium and low potassium intake might contribute 
to the development of hypertension1.  It has also been suggested that magnesium might 
have a role in the development of hypertension in that small changes in extracellular 
magnesium concentration or intracellular free magnesium contribute effects on cardiac 
excitability and vascular tone and contractility.  Low levels of magnesium may 
strengthen arterial response to vasoconstrictors and lower response to vasodilators, 
leading to increased peripheral resistance and blood pressure12.  Higher levels of 
magnesium have opposing effects that ultimately lead to vasodilation and reduced blood 
pressure12.  Finally, other risk factors include genetic predisposition and existing pre-
hypertension1. 
Hypertension is also a contributing feature of metabolic syndrome, a disorder 
defined by a cluster of associated risk factors.  The prevalence of metabolic syndrome is 
22-39% in developing countries and can be a predictor of heart disease and diabetes.  The 
development of hypertension with metabolic syndrome might result from increased 
weight and impairment in kidney function (with increased sodium reabsorption) and may 
be both a cause and effect of the associated hypertension14.  Many individuals with 
Metabolic Syndrome exhibit some degree of insulin resistance and increased central fat 
distribution.  Some investigators have postulated the contribution of hyperinsulinemia to 
hypertension in this setting.  Possible mechanisms include insulin’s ability to stimulate 
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sodium reabsorption at the kidney (an antinatiuretic effect) to stimulate the sympathetic 
nervous system11. 
 
Normal blood pressure regulation vs. pathophysiology  
In normal physiology, blood pressure is controlled by many factors and through 
multiple mechanisms working together to maintain arterial blood pressure within the 
normal range.  Blood flow is dependent on both cardiac output and total peripheral 
resistance.  Heart rate and stroke volume largely determine cardiac output (CO).  Heart 
rate is dependent on β-1 receptors controlled by sympathetic stimulation and cholinergic 
receptors, controlled by parasympathetic stimulation11.  Stroke volume is influenced by 
ventricular force of contraction and the filling pressure determined by intravascular fluid 
volume and venous capacitance.  Total peripheral resistance is influenced by mechanisms 
that act at local, regional, and systemic levels11.  
Responses to blood pressure elevation can occur in seconds (acute responses), 
minutes to hours (intermediate-acting responses), or days to weeks (late –acting).  Acute 
responses to increased arterial blood pressure include reduced peripheral resistance and 
cardiac filling pressure as well as heart rate and myocardial contractility.  
Chemoreceptors at the vasomotor center also respond to acute changes in blood pressure.  
Intermediate-acting responses to blood pressure changes involve the Renin-Angiotensin-
Aldosterone System (RAAS), antidiuretic hormone (ADH), and the renal juxtaglomerular 
apparatus. Finally, late-acting mechanisms include pressure natriuresis and diuresis.  
Specifically, an increase in blood pressure above the homeostatic set point results in an 
increase in sodium and water excretion11. 
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The actual pathogenesis of hypertension remains unclear as multiple inputs may 
contribute including the sympathetic nervous system, the kidneys, endothelin, nitric 
oxide, the kallikrein-kinin system, and the RAAS.  Each is presented briefly below with 
the exception of RAAS, which is discussed in greater detail in the following section. 
The kidney is ultimately responsible for blood volume and blood pressure control 
in the long-term.  Interestingly, patients with essential hypertension who develop renal 
failure have been cured of their underlying hypertension upon successful kidney 
transplantation from a donor with normal blood pressure.  Others have suggested a 
disorder of genetic origin in which there is a reduction in nephron number and 
hyperfiltration and glomerular pressure damage ultimately impair sodium excretion. Salt 
sensitivity is less of a concern in youth and appears to increase with age, such that by 70 
years of age, almost all hypertensive individuals are salt-sensitive11. 
The sympathetic nervous system influences vascular tone, cardiac output, and 
peripheral resistance.  In the initial increase in blood pressure, both heart rate and stroke 
volume are increased as well as tone, which might partially explain the initial increase in 
peripheral vascular resistance11.  Hyperactivity of the sympathetic nervous system has 
been reported in some studies on hypertension11.  Stimulation of this system leads to 
vasoconstriction, increased heart rate, increased norepinephrine plasma concentrations, 
and increased blood pressure10,11.  It has also shown to promote vascular hypertrophy, 
increasing wall thickness that can contribute to resistance11.  
Endothelin-1 is a peptide with vasoconstriction properties that plays multiple roles 
in various organs. Endothelin-1 is found in blood vessels and the kidney.  It has been 
suggested to promote inflammation by increasing oxidative stress in the vascular wall, 
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resulting in vascular remodeling and endothelial dysfunction16 which can contribute to 
increased peripheral resistance and organ damage that can occur with chronic 
hypertension. 
Nitric oxide (NO) is produced from nitric oxide synthase (NOS) during the 
conversion of its substrate L-arginine to L-citrulline.  In vascular endothelium, the nitric 
oxide diffuses to vascular smooth muscle to stimulate vasodilation and to prevent 
vasoconstriction.  Given its contribution to blood pressure regulation, inadequate 
production of NO might be a factor in the etiology of hypertension17.  Possible 
explanations of insufficient NO production include reduced nitric oxide synthase (NOS) 
expression and strong endogenous inhibitors of the enzyme.  These are ordinarily cleared 
by the kidney, but in renal failure, clearance is impaired. Finally, a deficiency in NO 
could be due to inactivation by superoxide anions or other reactive oxygen species 
(ROS)17. 
The kallikrein-kinin system opposes the RAAS. It is not well understood, 
especially in regards to the pathophysiology of hypertension.  Kallidin is a strong 
vasodilator that is formed from its precursor kininogen via the hydrolytic actions of 
kallikrein.  Kallidin is further hydrolyzed by this enzyme to form other peptides with 
vasodilatory properties, including bradykinin.  It is believed that these then bind to β-
receptors resulting in a series of chemical reactions that precede an influx of intracellular 
calcium ions that stimulate NO production via NO synthase.  This pathway can be 
inhibited by ACE which hydrolyzes bradykinin18. 
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The Renin-Angiotensin-Aldosterone System (RAAS) 
The RAAS has a significant role in the regulation of blood pressure and involves 
a cascade of events resulting in increased blood pressure.  Prorenin is a precursor to the 
aspartyl proteolytic enzyme responsible for the initiation of the RAAS pathway, renin.  
Biosynthesis of renin occurs in the juxtaglomerular cells of the renal glomerulus.  Mature 
renin results with proteolytic removal of a peptide from the N-terminus of its precursor 
and is secreted into renal and systemic circulation in response to a drop in perfusion 
pressure or sodium chloride delivery to the kidney and sympathetic stimulation19.  Renin 
is present in other tissues including the brain, adrenal glands, visceral adipose tissue, and 
possibly the heart and vascular tissues19.  Renin converts angiotensinogen into 
angiotensin I, a decapeptide with no known bioactivity.  Angiotensinogen is primarily 
made in the liver, but is also thought to be synthesized in the brain, kidney, heart, and 
adipose tissue.  While angiotensinogen plasma levels appear static, increased production 
results from increased glucocorticoids, estrogens, and inflammatory cytokines19.  
Angiotensin I quickly becomes activated upon removal of its C-terminal dipeptide, 
forming the octapeptide, angiotensin II.  This reaction is facilitated by ACE, a dipeptidyl 
carboxypeptidase.  ACE is thought to be present in vascular endothelial cells, renal 
proximal tubule cells, and neuroepithelial cells and is membrane-bound19.  Interestingly, 
it is suggested that plasma levels of ACE are reflective of clearance of bound ACE19.  
ACE also promotes vasoconstriction through its facilitation of bradykinin degradation.  
Angiotensin II binds to its type-1 (AT1) receptor, resulting in increased vasoconstriction, 
aldosterone secretion, and consequential sodium retention and reabsorption19-21.  It can 
 11 
also promote oxidative stress19.  In contrast, binding to its type-2 (AT2) receptor has 
opposing effects21. 
More recently, a new axis of RAAS has been discovered in which eventual 
conversion of both angiotensin I and angiotensin II result in production of the metabolite 
angiotensin-(1-7) by angiotensin-converting enzyme-2, ACE2.  Endothelium-dependent 
vasodilation results when the metabolite binds to its receptor, Mas, thereby antagonizing 
the hypertensive effects resulting from angiotensin II binding to AT1 receptor.  
Accordingly, this axis may play a counter-regulatory role against the well-known RAAS 
pathway21. 
 
Current interventions 
A first recommendation for the management of hypertension is to alter lifestyle 
habits, especially dietary choices and level of physical activity.  A common dietary 
recommendation for prevention is to reduce sodium intake to less than 1.5 grams (1500 
mg) per day.  Another approach is the DASH diet, or Dietary Approaches to Stop 
Hypertension, which promotes the consumption of fresh fruits and vegetables, whole 
grains, lean meats, and low fat or fat-free dairy products.  It recommends low fat, low 
cholesterol and low sodium foods1.  Other recommendations include potassium 
supplementation for lowering blood pressure in those with and without hypertension.  It 
has also been suggested to reduce alcohol consumption (chronic drinkers) and to limit 
intake to no more than 24 ounces of beer or 10 ounces of wine per day.  Less often 
recommended because of insufficient support includes calcium and fish oil supplements.  
Dietary advice is usually paired with recommendations to increase physical activity, 
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specifically to a minimum of 30 minutes each day, or most days of the week.  Weight 
loss for those who are overweight or obese is strongly suggested.  Other lifestyle 
recommendations include smoking cessation1. 
Such recommendations are frequently accompanied by pharmacological 
interventions that include a wide array of medications used in the employment of various 
inhibitory or antagonistic strategies or for exploitation of physiological control 
mechanisms to indirectly regulate blood pressure.  The multitude of inputs and 
consequent dynamic complexity underlying its pathology are invitational to the 
development of widely varying pharmacological agents for the attenuation of 
hypertension.  These medications include diuretics, beta blockers, calcium channel 
blockers, alpha blockers, alpha-beta blockers, nervous system inhibitors, vasodilators, 
angiotensin II receptor blockers, and angiotensin-converting enzyme (ACE) inhibitors1. 
Thiazide diuretics are often first prescribed and may be particularly effective in 
African Americans, in which salt sensitivity is most prevalent22.  The mechanistic actions 
of diuretics include decreased blood volume and cardiac output as a result of increased 
urinary excretion of sodium and water, as diuretics exert natriuretic effects.  Blood 
volume and cardiac output revert to normal within 6-8 weeks of treatment.  Additionally, 
vasodilation may increase due to reduced sodium and water in vessel walls23.  Diuretics 
include carbonic anhydrase inhibitors, loop diuretics, thiazides, and potassium sparing 
agents, each acting at different sites of the renal tubule23.  Beta blockers competitively 
antagonize β-adrenoreceptors to slow heart rate and are often used in combination with 
other hypotensive agents.  Calcium channel blockers antagonize L-type calcium channels 
of the heart and smooth muscles thereby inhibiting the movement of calcium inward.  
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They stimulate dilation of coronary arteries (to increase oxygen supply) and peripheral 
arterioles and decrease cardiac contractility24.  Alpha blockers are alpha-adrenergic 
antagonists that relax various muscles and promote vasodilation, countering the effects of 
norepinephrine25.  Angiotensin II receptor blockers competitively antagonize angiotensin 
II receptors to prevent vasoconstriction and promote the release of aldosterone and 
catecholamines26.  ACE inhibitors competitively inhibit conversion of angiotensin I into 
angiotensin II to prevent the potent effects of angiotensin II, as previously described. 
While the aforementioned pharmacologic agents may help attenuate hypertension, 
they are not without side effects that render them inconvenient to patients.  Diuretics 
offer some of the least amount of side effects, but do include the risk for electrolyte 
imbalances (especially hypokalemia, and hyponatermia), impaired glucose tolerance 
resulting in hyperglycemia and insulin resistance, metabolic acidosis, and lipid 
abnormalities among others23.  Also, there is increased risk for muscle weakness, fatigue, 
and leg cramps27 as consequences of increased potassium loss, as well as arrhythmias, a 
potential side effect of thiazides and loop diuretics23.  Common shared side effects of 
alpha and beta blockers include fatigue, dizziness, nausea, headache, upset stomach, and 
diarrhea or constipation25.  Side effects of beta blockers also include cold sensations in 
the extremities (hands and feet) and depression and heart rate may increase when taking 
alpha blockers27.  Calcium channel blockers share similar side effects but also increased 
risks for flushing, drowsiness, and tachycardia.  ACE inhibitors can cause similar effects 
as well as dry cough and sleep disturbances, increased risk for hyperkalemia25, skin rash 
and dysgeusia27. 
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The need for something more, a functional food 
In addition to their potential side effects, pharmacological interventions can be 
both costly and inconvenient.  According to the Center for Disease Control and 
Prevention, it was estimated that in 2010, $76.6 billion in the U.S. would be spent in 
hypertension-related health care, medication, and missed work days28.  In addition, there 
is insufficient education and instruction provided to hypertensive patients, partly due to a 
lack of insurance coverage or reimbursements for counselling and referrals to dietitians 
by primary healthcare providers1. 
Many hypertensive individuals are without healthcare insurance and therefore 
may be without treatment.  Consequently, there is a need for additional efforts in 
addressing hypertension, ideally in its prevention.  A less expensive but more convenient 
alternative is of interest.  Consumers in the US and most other developed countries are 
becoming acquainted with and accepting of food products offering additional health 
benefits (so called “functional foods”).  Given the high prevalence of hypertension, most 
consumers would predictably be interested in purchasing something that could help lower 
blood pressure or, if consumed often, potentially slow or impede progression of 
hypertension from a pre-hypertensive state.  Increased awareness and consumer 
knowledge of the relationship between diet and health has encouraged greater interest in 
exploring the possibilities of functional foods29, and dietary modifications including 
bioactive food substances are highly appealing.  The Academy of Nutrition and Dietetics 
describes its position as, “All foods are functional at some physiological level, but it is 
the position of the American Dietetic Association that functional foods that include whole 
foods and fortified, enriched, or enhanced foods have a potentially beneficial effect on 
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health when consumed as part of a varied diet on a regular basis, at effective levels,”30.  
Immediate benefits of a functional food designed to lower blood pressure would include 
its affordability, its availability, and its ability to preclude the side effects observed when 
taking antihypertensive medications. 
 
Bioactive peptides 
Researchers have found antihypertensive activity in dairy-derived peptides in in 
vitro, animal, and human studies.  The discovered bioactivity has stoked the interest and 
curiosity of researchers with the idea of developing functional foods that both attenuate 
high blood pressure and preclude the side effects associated with antihypertensive 
medications.  Bioactive peptides are specific fragments of proteins that have a positive 
influence on body functions and may enhance health.  Upon consumption, bioactive 
peptides can affect various systems in the body that include the digestive, cardiovascular, 
immune, and nervous systems and their target systems are contingent upon their 
individual amino acid compositions and sequences31.  Regarding hypertensive pathways, 
the majority of bioactive peptides have shown ACE inhibitory activity. 
Interestingly, ACE-inhibitory peptides were first identified in snake venom.  
Since then, many ACE-inhibitory peptides derived from animal and plants have been 
discovered.  Some sources include eggs through hydrolysis of ovalbumin, fish (salmon, 
sardine, anchovy, and Alaskan Pollack), as well as fermented fish sauce.  Plant sources 
include soybean protein and sesame powder protein29.  Milk or dairy-derived proteins are 
good sources of antihypertensive peptides. 
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In vitro production and characterization studies provide vital information for 
optimizing the development of peptides with ACE inhibitory properties.  However, the 
findings from studies examining in vivo effects on blood pressure post administration of 
these peptides reveal their true value and the probability for success of a functional food. 
The aim of this thesis project was to investigate the acute effects of dairy and soy 
protein-derived bioactive peptides on blood pressure in adult humans.  A systematic 
review of the current literature on dairy- and soy- derived ACE inhibitory peptides in 
animals and humans was conducted and is presented in Chapter 2.  Chapter 3 presents the 
pilot human study that was conducted for this thesis project, and Chapter 4 presents 
conclusions and directions for future research. 
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CHAPTER 2: A SYSTEMATIC REVIEW OF THE 
LITERATURE* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Portions of Chapter 2 are in preparation as a manuscript for possible publication 
as a systematic review. 
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Introduction 
Referred to as ‘the silent killer,’ hypertension is the most prevalent cardiovascular 
disorder that is both chronic and often asymptomatic.  It is estimated to affect 33% of 
Americans1 and 1 billion people worldwide2.  A first recommendation for management is 
to address lifestyle habits, especially diet and physical inactivity.  Sodium restrictions to 
less than 1500 mg per day and the Dietary Approaches to Stop Hypertension (DASH) 
diet, which promotes the consumption of fresh fruits and vegetables, whole grains, lean 
meats, and low fat or fat-free dairy products have been prescribed1.  Pharmacological 
interventions are effective treatments, but are often accompanied by undesirable side 
effects.  According to the Center for Disease Control and Prevention, it was estimated 
that in 2010, $76.6 billion in the U.S. would be spent on hypertension-related health care, 
medication, and missed work days28.  There is a need for alternative approaches to 
address hypertension, ideally focusing on its prevention.  A less expensive and more 
convenient alternative to antihypertensive medications is of interest.  Increased consumer 
awareness of the relationship between diet and health supports investigation into the 
possibilities of functional foods29 and dietary modifications including foods that contain 
bioactive substances.  Immediate benefits of a functional food designed to lower blood 
pressure or impede progression of a hypertensive state would include its affordability, 
convenience and availability, and its lack of undesirable side effects compared to 
pharmacologic approaches. 
Researchers have found antihypertensive abilities in dairy-derived peptides in in 
vitro and in vivo animal and human studies.  This potential bioactivity has stoked the 
interest and curiosity of researchers with the idea of developing functional foods that both 
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attenuate blood pressure and preclude medication-related side effects.  Bioactive peptides 
are protein fragments encrypted within an inactive protein sequence with biological 
functions that may enhance health.  These peptides can affect various systems in the body 
that include the digestive, cardiovascular, immune, and nervous systems, and have been 
shown to exert antioxidant effects31,32; their target systems are contingent upon their 
individual amino acid compositions and sequences31.  The majority of antihypertensive 
bioactive peptides are believed to exert effects though ACE-inhibition with dairy-derived 
peptides studied most extensively.  Though much less studied, soy-derived peptides are 
of interest, considering the many potential benefits already associated with soy-based 
diets.  
In vitro production and characterization studies provide vital information for 
optimal development of peptides with ACE inhibition.  Consequently, much attention has 
been paid to this area of research.  However, the true worth of these peptides, and by 
extension, the success of a functional food containing these peptides, requires the 
evaluation of their blood pressure lowering capabilities in vivo, particularly in human 
subjects. In order to assess current understanding of their in vivo potential, we reviewed 
the literature on dairy- and soy- derived ACE inhibitory peptides in animals and in 
humans with the purpose of presenting the findings of animal and human-based studies 
on blood pressure reduction and/or ACE-inhibition following acute or chronic 
administration of dairy- or soy-derived bioactive peptides. 
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Methodological approach to systematic review 
A systematic review was conducted on the in vivo animal and human-based 
studies on the antihypertensive effects of dairy- and soy-derived bioactive peptides and 
the renin-angiotensin system, specifically ACE-inhibiting peptides using a multi-database 
search with the following databases with no limitations by year: In Process, Ovid 
Medline (R), Agricola, Agris, Biological Abstracts, Biosis Previews, CAB Abstracts, and 
Food Science and Technology Abstracts. Additionally, Cochrane, Web of Science, and 
Pubmed were also searched.  The following sets of search terms were entered in the 
formats shown below and were searched separately: 
 
hypertension OR blood pressure* OR antihypertensive agent* OR antihypertens* 
OR antihypertensive activity* OR angiotensin-converting enzyme inhibition OR 
angiotensin-converting enzyme inhibitor* OR ACE inhibitor* OR peptidyl-
dipeptidase A OR kininase II OR angiotensin-converting enzyme* OR 
angiotensin* OR renin-angiotensin system OR angiotensinogen OR renin 
 
bioactive peptide* OR bioactive amino acid* OR physiologically active peptide*  
 
soybean protein* OR soy protein* OR soybean derived peptide* OR soya 
protein* OR glycinin OR conglycinin* OR beta conglycinin* 
 
milk protein* OR milk peptide* OR dairy protein* OR whey isolate* OR whey 
protein isolate* OR whey protein hydrolysate* OR whey hydrolysate* OR 
casein* OR lactotripeptide* OR lactoglobulin* OR alpha lactalbumin* OR alpha-
La OR lactalbumin* 
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The search strategy involved combining the above term sets as described: the set 
of terms that include “bioactive peptide*” and the set beginning with “milk protein*” 
were searched together joined by AND.  The set beginning with “bioactive peptide*” was 
also searched along with the set that begins with “soybean protein*” using AND in the 
databases.  The results from the aforementioned two searches were combined by OR and 
these results were finally joined with the set of terms beginning with “hypertension,” 
joined by AND.  Terms that could be exploded were so, in an effort to optimize database 
searches.   
Following this strategy, a total of 843 from 885 articles were found after limiting 
to articles in the English language.  After removing duplicates, a total of 438 articles 
remained.  Articles whose central theme did not pertain to dairy- or soy- derived peptides 
and ACE inhibition or blood pressure lowering were excluded, as were case studies and 
reviews.  Figure 1 below presents the exclusion process: 
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Figure 1. Multi-database search results and the exclusion process 
Total articles   885 
English only   843 
Duplicates removed  438 
      -   203 (Irrelevant central theme) 
      -  0 (Case studies/reports) 
      -  121 (Reviews) 
     114  Remaining articles 
         +  8 Articles found elsewhere 
 
     122  Total articles 
 
 
 
Production of bioactive peptides 
Bioactive peptides are usually inactive within the parent (protein) sequence, 
necessitating hydrolytic release for bioactivity.  These peptides are produced primarily 
through hydrolysis during bacterial fermentative processes or when treated with isolated 
or combined proteases derived from various sources.  An important benefit to the 
identification and use of various enzymes or enzyme systems is the formation of a variety 
of peptides, each possessing different bioactive potential.  Two frequently used methods 
for production, as previously mentioned, rely on fermentation with bacterial sources and 
treatment with isolated or combined enzymes from various sources and an overview of 
sources of each are presented. 
28 human studies 34 animal 
 
60 in vitro 
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Dairy-derived ACE inhibitory peptides: sources for fermentation 
Hydrolysis can occur with bacterial fermentation, most often using lactic acid 
bacteria (LAB), in which several proteolytic enzymes released from starter cultures assist 
in protein degradation33.  The type of starter culture used in dairy products is an 
influential factor in successful development of these peptides34.  Consequently, 
investigations on bacteria strains and peptide yields are of great interest to researchers in 
this area.  Bacteria used in fermentation processes in the production of bioactive peptides 
have included (often mixed) cultures containing strains of Streptococcus thermophilus34, 
Lactobacillus delbrueckii subsp. bulgaricus34,35, Streptococcus thermophilus TH4, 
Lactobacillus acidophilus LA5, and Bifidobacterium bifidum Bb1234.  Others include 
various species of Lactobacillus, such as Lb. helveticus36-38, Lb. brevis, Lb. paracasei, Lb. 
acidophilus, and Lb. bifermentan, L. lactis subsp. cremoris FT437-39.  The microflora of 
various cheeses have also been used for fermentation33 as well as isolated strains of 
Enterococcus faecalis from raw cow milk40.  Other studies have used probiotics during 
cheese ripening processes to determine ACE-inhibitory peptides and their activities41 or 
have examined  the food-grade production and stability of casein-derived ACE-inhibitory 
peptides42.  Finally, efforts toward optimization of peptide yields have led to the advent 
of combined method strategies, including the use of LAB fermentation with added 
protease43. 
 
Dairy-derived ACE inhibitory peptides: sources for enzymatic hydrolysis 
Enzymatic hydrolysis is used for bioactive peptide production.  Some 
investigators have conducted hydrolysis with single digestive proteases or varying 
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combinations of pepsin, trypsin, and chymotrypsin33,34,44-51.  Others have used combined 
enzyme treatments such as pepsin and pancreatin to digest human milk and infant 
formula52.  The incubation of proteins with isolated bacteria-derived enzymes is another 
common method of enzymatic hydrolysis.  Such proteases are derived from the 
frequently used Bacillus thermoproteolyticus-derived thermolysin,53, Flavourzyme54, or 
other fungal proteases derived from Aspergillus oryzae43,55, proteinase K, from 
Tritirachium album45,46, Bacillus licheniformis protease45, and Actinase-E , derived from  
Actinomyces ssp47.  Some investigators have used a commercial proteolytic mixture from 
Bacillus subtilis, Protease N Amano56 for the development of ACE-inhibitory peptides. 
Finally, interesting alternative origins of enzymes include plant sources, such as C. 
cardunculus57 and papain from Carica papaya47.  Additionally, the enzyme Corolase PP, 
a proteolytic mixture from the pancreas glands of pigs that includes trypsin, 
chymotrypsin, and several amino and carboxypeptidases58 and its ACE-inhibitory peptide 
yield have been included in studies44,49. 
 
Soy-derived ACE inhibitory peptides: sources for enzymatic hydrolysis 
The production methods for yielding soy peptides mirror those employed for the 
dairy-derived counterparts in that processes include the use of mammalian digestive, 
bacteria- and mold-derived enzymes and fermentation, or a combination of these. 
Specifically, some investigators subjected soy protein to pepsin and pancreatin treatments 
for peptide production59,60.  Other enzymes used in the production of soy-derived 
peptides have come from bacterial sources including Bacillus subtilis61 and Bacillus 
licheniformis, responsible for producing the commonly used enzyme, alcalase62,63.  Other 
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researchers have produced peptides using treatments with proteases derived from molds, 
specifically Monascus purpureus, a commonly used fungus for the production of certain 
fermented foods64and strains of Aspergillus oryza61,63,65.  Furthermore, peptides produced 
from probiotics including Lactobacillus acidophilus in soy whey medium have been 
investigated66.  Finally, others have compared bioactive peptide productions from various 
enzymes using digestive enzymes, pepsin, trypsin and chymotrypsin, with various 
commercial enzymes63,67 and ginger protease from ginger, Zingiber officinale67. 
The development of dairy- and soy- derived ACE inhibitory peptides has largely 
relied on proteolytic systems of fermentative processes as well as hydrolysis with isolated 
or combined enzymes.  Success and diversity in their production can be at least partly 
ascribed to the use of a number of bacterial, fungal, and plant sources.  An important 
benefit to the wide array of enzymes and enzyme systems used for production is the 
ability to derive bioactive peptides with varying potential, thereby increasing the 
likelihood of discovering peptides with potent bioactivity.  
 
ACE inhibition in vitro 
How is ACE inhibition expressed? 
The determination of ACE inhibition by an antagonist, such as a bioactive 
peptide, in an in vitro study is most often conveyed as the half maximal inhibitory 
concentration (IC50) of the inhibitor.  Essentially, this value describes the concentration of 
the substance needed to inhibit the enzyme by half of its original activity.  Accordingly, a 
lower IC50 value signifies greater potency, as less of the inhibitor is required to inhibit to 
half the enzymatic activity68.  Conversely, a higher value would imply less potency.  As 
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expected, these values are highly variable among bioactive peptides.  Although much 
more potent than any bioactive peptide studied, Captopril, an ACE-inhibitor drug, is 
often used for comparison, with an IC50 reported to be around 0.006µmol/L51.  It is also 
often expressed as percentage (%) of ACE inhibition at a given protein concentration.  
Though there are other methods to arrive at this value, several studies have employed 
spectrophotometric absorption measures and have used the following formula (or some 
version of this):  
% Inhibition activity = (A-C) / (A-B) X 100; where: 
  A = the optical density without the peptide fraction 
  B = the optical density without ACE 
C = the optical density with both the peptide fraction and ACE 
 
What effects do time and degree of hydrolysis have on in vitro ACE-
inhibition? 
As the generation of bioactive peptides is dependent on hydrolysis of the parent 
protein, speculation about the effects of hydrolysis time on their production has led to 
further investigation.  Equally as important as the enzymes selected for production of 
ACE inhibitory peptides is the determination of optimal time of exposure to the enzyme 
and the degree of hydrolysis.  
The plausibility that increased hydrolysis time yields more potent bioactive 
peptides has been supported by researchers observing lower IC50 values or higher percent 
(%) inhibitory activities with increased hydrolysis time, or degree of 
hydrolysis34,45,51,54,56,61,69.  However, some researchers infer that a maximum ACE 
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inhibition exists, minimizing or eliminating the need for extended hydrolysis time45,70 
though ACE inhibition has been observed to correlate with degree of hydrolysis 71.  
Observations of plateaus in ACE-inhibitory activities with time56 and early release of 
such peptides without further production with increased hydrolysis44 are congruent with 
the previous suggestions.  Furthermore, the maintenance of the ACE inhibition with 
increased hydrolysis time could result from resistance to further degradation or, 
conversely, the formation of new peptides upon degradation, thereby lending balance45.  
Associations may partly depend on the enzyme or enzyme mixture and its proteolytic 
activities; given that it has been observed that some hydrolysates associated with the 
highest degrees of hydrolysis resulted in lowest ACE -inhibitory activities, possibly 
owing to a combination of endopeptidase and exopeptidase activities63.  The presence of 
both could result in cleavages at various sites of the peptide chain, precluding 
bioactivity63.  In contrast, others found that increased growth of a probiotic in a soy-based 
medium correlated with increased ACE -inhibitory activity, potentially due to a 
proteolytic system comprised of several peptidases and proteases essential for cell growth 
and survival that releases such peptides72.  Importantly, the degree of hydrolysis does not 
necessarily correlate with enzyme exposure time as nearly immediate increases in degree 
of hydrolysis followed by plateaus with further time advancement has been reported73.  
Similar trends have been observed with ACE- inhibitory activity73.  Finally, researchers 
have observed changes in ACE inhibitory activity upon subsequent treatments with other 
enzymes73,74 and time of exposure and degree of hydrolysis with one treatment may 
affect susceptibility to cleavage of peptides during exposure to a second enzyme 
treatment74.  Interestingly, it has been observed that heat pre-treatments of peptides might 
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enhance digestibility/proteolysis74.  Nonetheless, greater complexity is introduced when 
differences in protein and enzyme types and their associated hydrolysis times for 
maximum ACE -inhibitory peptide release are considered46,51.  Such complexity presents 
challenges for the production of bioactive peptides with optimal potencies.  
 
Do the bioactive peptides survive digestion? 
While in vitro ACE inhibition observed in food-derived substances inspires 
thoughts of functional food opportunities in industry, researchers recognize that 
appreciable in vivo effects require that the ingested bioactive peptides surmount an 
important obstacle: digestion.  Though results of many in vitro studies have readily 
revealed peptides with ACE-inhibitory activity, only some have subjected these to the 
digestive proteases pepsin, trypsin, and chymotrypsin.  As one might expect, some 
peptides lost potency upon hydrolysis57,64, while other studies reported peptide survival 
from enzymatic cleavage, likely due to short peptide chains (4-7 amino acids)35,38,75-77.  In 
accordance with previous speculations, other investigations revealed little or no changes 
in inhibitory ability33,38,57,58,62-64,67,77,78, or increased ACE -inhibitory potential43,57,64,77 
after exposure to digestive proteases.  An explanation, as previously mentioned, for the 
latter observation is that either the original peptide resisted further hydrolysis or its 
hydrolysis yielded smaller bioactive peptides with greater chance for survival from 
further proteolytic cleavage33,43,49,57,64,77.  Importantly, it has been suggested that the 
presence of other peptides may impose a change of fate upon a peptide previously tested 
in isolation.  Specifically, Roufik et al79 observed that when long- and short- chain 
peptides are combined (as seen in vivo) there is increased hydrolysis, even among those 
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that, when alone, resist hydrolysis.  Furthermore, these researchers also considered the 
influence of pH changes (i.e. stomach to small intestine), noting altered susceptibility to 
hydrolysis as a consequence of modified charges within the peptide79.  Other researchers 
have suggested the potential influence on potency of the stage of digestive processes at 
which peptides are absorbed on potency and the possibility of absorption of long peptide 
chains that then may act in synergy or cumulatively with shorter peptides to enhance 
overall blood pressure lowering effects74.  In effect, researchers assert that the 
applications of theoretical specificity regarding digestive proteases and in vitro digestion 
warrant caution in their prediction of outcomes of bioactive peptides after digestion, and 
that important variables, including chain length and the presence of other peptides, 
support the need for in vivo studies79.  Interestingly, researchers have suggested that the 
ability of small peptides to be absorbed easily in intact form may be due to unique uptake 
systems62 or through transcytosis from the gut into circulation 80. 
 
What is known about peptide sequence and structure, in relation to in vitro 
ACE inhibition? 
It is well-accepted that hydrophobic amino acids, especially with aromatic or 
branched side chains occupying the three C-terminal positions of a peptide instill potent 
inhibitory potential38,48-51,65,74,76,77 and are likely accommodated by the three subsites of 
the carboxyl domain of the catalytic site, S1, S1', and S2', like the three C-terminal 
residues of angiotensin I (phenylalanine, histidine, and leucine)34,53,57,81.  It has also been 
suggested that the most potent include aromatic residues (tryptophan, tyrosine, or 
phenylalanine), the (imino) amino acid proline, arginine, with the positive charge on its 
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guanidine group side chain at the ultimate position34,37,51,53,64,74, as well as leucine, owing 
to the positive charge on the epsilon-amino group56.  It has also been suggested that a 
proline residue at the antepenultimate position contributes significantly to potency34,38,48-
50,77.  It is recognized that dicarboxylic amino acids are least potent34,82.  Most ACE-
inhibitory peptides are comprised of 2-12 residues, but they can be as many as 27 
residues in length71.  Regardless, ACE appears to have wide substrate specificity, a 
possible consequence to the presence of two active sites62,67.  While it seems that much 
has been learned regarding substrate preference for ACE, the actual structure-function 
relationships of these peptides is unclear38,67,71,82 and individual and occasionally 
conflicting observations contribute to the complexity of the picture.  For example, 
positive correlations between side chain hydrophobicity and potency and between side 
chains without positive charges occupying the C-terminal end and potency have been 
suggested by some74.  Others observed a reduction in potency associated with the size of 
the side chains of the neighboring residue of the C-terminus and a positive contribution 
from residues with positive charges74.  Furthermore, some researchers suggest a possible 
influence on peptide potency of N-terminal residues, potentially enhancing potency or 
greater ACE affinity when occupied by branched chain amino acids, though this appears 
to be neither essential62,65,67, nor well-supported77 and most studies focus on the C-
terminal occupants.  Potency could also be influenced by the conformers resulting from 
the preparation of bioactive peptides, particularly of those containing proline, most often 
when present at the C-terminus.  Specifically, it was found that the trans form was more 
potent than the three cis conformers studied, offering a reason for differences found in 
ACE inhibition between peptides with the same primary sequences83.  Finally, although 
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some studies report mixed inhibition43 most support the competitive inhibition of 
bioactive peptides34,40,84,85.  In contrast to the identification and characterization of ACE-
inhibitory peptides, other investigations identified casein-derived peptides with 
bradykinin-potentiating abilities and that may act as opiates86.  While in vitro findings are 
important for optimal production of peptides that survive digestion and absorption 
processes with predictive ACE- inhibitory effects, inarguably, the in vivo effects 
ultimately define their worth.  
 
Assessing the significance of blood pressure reduction in humans 
Investigators have evaluated the in vitro and in vivo potential of bioactive peptides 
to inhibit ACE and/or lower blood pressure.  Before discussing the relevant human 
studies of bioactive peptides, in particular, it is useful to consider the potential clinical 
relevance or public health implications when evaluating blood pressure reductions, even 
when these may not be found to be statistically significant in studies with small sample 
sizes.  A reduction in SBP of 2 mm Hg may reduce risks for stroke and MI by about 
4%87,88, and reductions of 3-5 mmHg in SBP is associated with reduced risks for stroke 
and MI by 15% and 10%, respectively89.  It has also been found in clinical trials on blood 
pressure medications that a mean reduction in DBP by 6 mmHg is associated with a 40% 
reduction in stroke risk90. 
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Whey-derived bioactive peptides 
Whey protein 
A by-product of cheese making68,91, whey is a heterogeneous mixture of proteins 
with bioactive and functional food potential that accounts for approximately 20% of total 
milk protein68,92.  Once considered a waste product or something to be made into low 
value products68,92, advancements in technology are unveiling whey protein’s true worth 
through further discovery of its physiological potential92.  Interestingly, its use in 
products only began in the early 1990’s, primarily as an additive to sports nutrition 
products.  Its use was favorable because of its digestibility, efficient absorption, and 
ample supply of branched chain amino acids68.  Devoid of flavor, whey proteins are also 
used to enhance the protein content of food products without sacrificing or altering 
product taste68.  With employment of various technologies, whey proteins can be 
processed into powders, concentrates, isolates, and hydrolysates68 for various purposes. 
Whey protein is a composite of various protein fractions including α-
lactoglobulin, immunoglobulin, and bovine serum68,93.  Its main fractions, comprising 70-
80% of whey protein, are α-lactalbumin (α-La) and β-lactoglobulin (β-Lg)92-94.  More 
specifically, β-Lg is a small globular protein of 162 amino acids in length and is 
considered the major bovine whey protein, accounting for about 50% of the total 
whey91,92,94, though an estimate of 60% contribution has been previously suggested82.  α-
La is the second major protein (accounting for 20-25% of bovine whey), comprised of 
123 amino acids91.  Furthermore, minor whey proteins include lactoferrin, 
immunoglobulins, and proteose-peptones that are believed to have antimicrobial 
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activities93.  Whey-derived bioactive peptides with ACE -inhibitory or blood pressure 
lowering abilities have been termed lactokinins34.  Though not as well-studied as casein, 
current research supports whey as an excellent source of bioactive peptides, thereby 
keeping researchers resolute in their quest for further discovery. 
 
Antihypertensive effects of whey-derived peptides in vivo: animal studies  
At present, the vast majority of work on whey-derived peptides with ACE 
inhibition/blood pressure lowering potential has been in vitro-based studies.  This section 
discusses the limited number of in vivo and ex vivo investigations that tested for blood 
pressure lowering effects using animal models. 
 
Ex vivo ACE inhibition  
Although ex vivo studies do not take into account the susceptibility of bioactive 
peptides to further hydrolysis during digestion and absorption processes, they allow for 
the ability to directly examine and confirm the potential for peptides to inhibit ACE in 
animal tissue.  A study by Centeno et al81 used in vitro studies on ACE inhibition from 
lactoferricin B- related peptides compared to synthetic hexapeptides to determine the 
most potent ACE inhibitors that were then further examined in ex vivo functional assays.  
Lactoferricin B (Lfcin B) is a peptide consisting of 25 amino acid residues derived from 
the whey fraction, lactoferrin81.  The ex vivo studies required dissection of the common 
carotid arteries of 30 male white rabbits.  Following washout from exposure to 
angiotensin I, each segment was exposed to one of the following: a second exposure to 
angiotensin I, two exposures to angiotensin II, separated by exposure to Captopril as a 
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negative control, pre-incubation with Captopril (from 1nM to 1 µM) followed by a 
second exposure to angiotensin I, or pre-incubation with one of the ACE inhibitory 
peptides (20 µM) followed by a second exposure to angiotensin I.  A second 
measurement of contractile capacity response followed the treatments, expressed as the 
percent of the respective first contraction.  As expected, angiotensin I provoked transient 
contractions in arterial segments.  As one might expect from a potent ACE inhibitor, in 
segments pre-incubated with Captopril at 1 µM, this contraction was unobserved, though 
returned following wash-out.  In contrast, Captopril did not affect the angiotensin II-
induced contractions, supporting that angiotensin I is responsible for ACE-dependent 
contractions and that formation of angiotensin II is required for the vasoconstriction.  
Interestingly, the 5 peptides exerted different inhibitory effects on contractions, only one 
of the two Lfcin B-derived peptides of which significantly reduced angiotensin-I induced 
contractions along with two of the three synthetic peptides. 
Results from this study support many in vitro studies which suggest that whey-
derived blood pressure lowering peptides may exert their effects through ACE inhibition, 
in part by inhibiting angiotensin-I induced contractions.  However, other mechanisms 
have been explored and are presented next. 
 
The potential for other mechanisms for blood pressure reduction 
Investigations into the antihypertensive abilities of bioactive peptides largely 
focus on ACE inhibition.  However, some researchers have investigated the potential for 
other mechanisms behind the observed blood pressure lowering effects of these peptides.  
These other mechanisms include the ability of certain peptides to antagonize the AT1 and 
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AT2 subtype receptors of angiotensin II95.  Another suggestion is the potential ability of 
certain peptides to bind to opioid receptors; some have been found to lower blood 
pressure through vaso-relaxation, as described next.  
Derived from hydrolyzed α-La, α-lactorphin is a peptide comprised of four 
residues (Tyr-Gly-Leu-Phe) that is believed to possess both opioid-like and ACE-
inhibitory potential96.  In a multifaceted study, relationships between subcutaneous 
administrations of α-lactorphin and blood pressure in spontaneously hypertensive rats 
(SHR) and normotensive Wistar Kyoto rats (WKY) were examined and revealed dose-
dependent reductions in the blood pressure of SHR.  The lowest dose capable of 
attenuating blood pressure was 10µg/kg.  Interestingly, maximum reductions in blood 
pressure did not result from the highest dose administered (1mg/kg), but after injection of 
100 µg/kg.  This maximal effect was reached 50-100 minutes post-administration and 
reverted to baseline values by 200 minutes.  No significant blood pressure lowering effect 
was observed after administration of any of the individual amino acids that comprise α-
lactorphin.  The dose-response relationship for blood pressure in WKY rats was quite 
similar to SHR, resulting in reductions of 16 and 12 mmHg for systolic and diastolic 
blood pressures, respectively, at a dose of 100 µg/kg.  A unique feature to this study is 
the use of antagonists to help establish a mechanism, or to rule out potential contributors 
to the observed blood pressure lowering effect.  Researchers employed pre-treatment 
experiments in which SHR received either a bradykinin B2 receptor antagonist, an opioid 
receptor antagonist, or saline 30 minutes prior to administration of 100 µg/kg α-
lactorphin.  The bradykinin B2 receptor antagonist did not affect blood pressure or the 
effect of α-lactorphin administration on blood pressure.  Similarly, blood pressure was 
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not affected by the lower doses of the opioid antagonist; however, a significant decrease 
in both SBP and DBP at higher doses was observed.  Interestingly, the hypotensive 
effects exerted by α-lactorphin at its most influential dose of 100 µg/kg was antagonized 
and reversed, resulting in a hypertensive response.  These findings suggest that the 
mechanism behind the ability of α-lactorphin to reduce blood pressure involves opioid 
receptors.  
 
The effects of acute and chronic whey treatments in SHR 
Some studies have investigated the in vivo blood pressure lowering effects of a 
single dose of whey protein treatment.  In a study by Muguerza et al40, after fermentation 
with wild strains of bacteria and assessment of in vitro ACE-I activity, samples of whey 
fractions with highest ACE inhibition were administered to male SHR and WKY through 
gastric intubation as a single dose of 5 ml/kg (or about 1.5 ml) of either water or 
unfermented milk or as 50 mg/kg Captopril in a deionized water solution.  Treatments 
with the fermented milk samples resulted in a similar degree of reduction in DBP to that 
observed with Captopril, but a lower reduction in SBP.  In addition, the maximum 
lowering effects were observed in the fermented milk groups sooner, around 4 hours 
post-administration, compared to Captopril (6 hours).  Blood pressure returned to near 
baseline values 24 hours after treatments.  In contrast to findings from other studies96, 
these researchers observed that none of the treatments lowered blood pressure in 
normotensive rats, suggesting safety for use as a functional food without posing risk to 
normotensive individuals40. 
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A study conducted by Tsai et al43 employed a combined method of lactic acid 
fermentation and proteolysis of milk to determine the blood pressure lowering effects of a 
chronic administration of fermented whey.  Using the most potent fraction, oral 
administration of 150ml of diluted fermented milk whey was given to 8 SHR.  The 
increase in SBP by 12 weeks in the control and treatment groups was significantly 
different; the SBP in the fermented whey group was lower, signifying a slowed 
progression in the development of hypertension.  After continued oral administration for 
8 weeks, the SBP of the treatment group was significantly lower than the control, with an 
average reduction of 15.9 mmHg.  A similar trend was observed in DBP, with values 
increasing with age and significant differences not apparent until later in the experiment.  
The use of analytical techniques allowing for determination of the fraction sequence, 
further use of in vitro ACE inhibition assays, and confirmation of survival from digestion 
allowed researchers to confidently infer that this fraction of the whey hydrolysate was the 
main contributor to the observed blood pressure lowering effects. 
 The findings of these studies support the ability of acute and chronic doses of 
hydrolyzed whey to reduce blood pressure in SHR.  Furthermore, the potential for safety 
following ingestion of antihypertensive peptides in normotensive rats is suggested. 
 
Does in vitro ACE inhibition equate to in vivo blood pressure reduction? 
The worth of in vitro investigations is evident.  These studies provide information 
on optimal production of peptides, their structure-activity relationships, and they have 
demonstrated that potency can be lost, maintained, or increased following further 
hydrolysis with digestive proteases.  However, as previously mentioned, researchers 
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suggest that such findings need to be taken with caution and that the potential  for other 
influences including the presence of other peptides, chain length, and pH changes during 
passage from the stomach to the small intestine may alter susceptibility to further 
cleavage, rendering peptides more or less potent79. 
 Murakami et al95 examined the in vivo effects on SBP of ACE-inhibitory peptides 
derived from whey, casein, ovalbumin (from egg white), wheat gluten, and soybean 
administered to SHR through gastric intubation (in a solution of 2 mg peptides/2 ml 
distilled water).  Blood pressure measures were taken before and 6 hours after 
administration.  The greatest change was observed in a whey-derived protein treatment 
group (- 21.2 ± 16.9 mmHg).  It is interesting to note that while a sample from ovalbumin 
scored the highest percent inhibition of ACE in vitro (shared by a whey sample, 78.2%), 
it exerted the weakest antihypertensive effects in vivo.  In contrast, samples of whey and 
casein scored medium degrees of ACE inhibition (defined as >51% inhibition), but 
exerted strong antihypertensive effects, with reductions greater than 18.0 mmHg.  
Furthermore, when the whey fraction showing the strongest in vivo antihypertensive 
effects was subjected to further fractionation, with its sub-fractions tested for ACE 
inhibition, only one showed inhibition with an IC50 of 928µM (considered very weak 
inhibition).  Upon administration of this peptide fraction to another group of 5 SHR, 
subsequent blood pressure measurements revealed decreases of about 19.0 mmHg at 6 
hours and  21.4 mmHg at 8 hours, both significantly different from the control group.  
Blood pressure values nearly reached baseline after 10 hours post-treatment.  The 
findings of this study support the need for human-based evaluation as the quantified 
potencies of certain peptides in vitro were not supported by in vivo observations. 
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Accordingly, research on humans is essential before functional foods with blood pressure 
lowering ability become widely available. 
  
Antihypertensive effects of whey-derived peptides in vivo: human studies 
Whey-derived bioactive peptides on blood pressure attenuation in humans have 
not been well-studied, although conflicting results from in vitro and in vivo studies and 
the development of functional foods containing these peptides underscore the need for 
studies in humans.  In an extensive search with eleven databases, only two studies 
investigating whey-derived peptides in humans were found, both assessing the effects of 
chronic intake of whey hydrolysate.  
Pins and Keenan97 conducted the first human pilot study to determine the 
antihypertensive and other cardiovascular effects of a whey protein hydrolysate.  Thirty 
subjects were randomized to either the active protein group (containing 20g of 
hydrolyzed whey protein) or the control protein group (unmodified whey protein) to 
consume without food each day for 6 weeks.  By the end of the first week, there was a 
mean SBP reduction of about 8.0 mmHg and a DBP reduction of 5.5 mmHg in the 
treatment group.  Analyzing both size and duration of change with an AUC approach, an 
AUC decrease in SBP during the experimental period (from weeks 1-6) revealed a 
significant 216 ±24 mmHg reduction for the treatment group, compared to a 27 ±19 
mmHg reduction for controls (a difference of 189 mmHg).  Significant differences 
existed for DBP as well, with reduction of about 151 mmHg for treatment and 33 mmHg 
for control, a net difference of 118 mmHg.  Furthermore, it was discovered that the whey 
protein hydrolysate reduced total cholesterol and LDL-cholesterol (both by 13%).  
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Findings of this study support general findings from in vitro and in vivo animal work, that 
bioactive peptides can lower blood pressure in vivo and may offer additional benefits.  
However, it should be noted that a retraction was made to this study due to reporting of 
falsified data98. 
Regardless, the results from the Pins and Keenan study were not supported by 
findings from a study by Lee et al99.  In this study, 54 hypertensive subjects were asked to 
ingest either 125 ml of a milk drink treatment that contained whey peptides or placebo in 
the morning for 12 weeks.  It was found that no significant changes occurred in blood 
pressure from the beginning to the end of the experiment.  Although IC50 data were not 
provided, it is worth noting that these peptides were tested for ACE inhibition by other in 
vitro tests.  Results of this study do not support the findings of Pins and Keenan.  The 
conflicting results of the two human studies presented exemplify the need for more 
human-based studies when considering the blood pressure lowering potential of whey-
derived bioactive peptides. 
 
Casein-derived bioactive peptides  
Casein and the lactotripeptides 
Accounting for around 80% of milk protein, casein encompasses a family of 
phosphorylated proteins that include αS1, αS2, β, and κ-caseins that aggregate together in 
milk, forming casein micelles93.  Caseins provide a wealth of amino acids upon digestion 
as well as calcium and phosphorus; the fragments bound to these minerals are called 
casein phosphopeptides and have been studied for various interests93.  Industrial use of 
casein includes sodium caseinate, a precipitate of casein micelles, as an emulsion 
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stabilizer93.  Interestingly, certain casein-derived peptides are found to possess opioid-like 
activity similar to morphine and have been termed casomorphins, with most originating 
from β-caseins and to increase gastrointestinal transit time and prevent diarrhea93.  
Furthermore, κ-casein derived peptides have been termed casoxins, and act like opioid 
antagonists.  Casein-derived peptides, IPP and VPP, are the most extensively studied 
ACE-inhibitory peptides and are referred to as the lactotripeptides.  These have been 
incorporated into commercial fermented beverages, including Calpis (Calpis Co., Ltd, 
Shibuya, Tokyo) and Evolus (Valio Ltd., Finland). 
  
Antihypertensive effects of casein-derived peptides in vivo: animal studies 
Casein-derived peptides may improve renal and overall cardiovascular 
health 
There have been several studies in animal models that have examined the effects 
of casein-derived peptides on ACE inhibition and blood pressure reduction, several of 
which report additional improvements to cardiovascular-related and renal health that may 
contribute to blood pressure reduction.  
Some investigators100 have found that supplementation with β-casein rich 
hydrolysate from goat milk in young SHR for 12 weeks partly prevented increases in 
SBP, with significantly lower measurements than the control group.  Furthermore, the 
hydrolysate-supplemented diet strongly prevented renal hypertrophy, significantly 
increased vasodilation in response to acetylcholine in aortic rings, and significantly 
reduced ACE activity in the heart, aorta, and kidney of SHR compared to other groups.  
In agreement, others noted reductions or delayed increases in SBP in SHR after 
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administrations of casein-derived peptides as well as improved relaxation in 
precontracted arterial101,102 and mesenteric103 rings, and reduced left ventricular 
hypertrophy103.  One study observed time-dependent relationships between tripeptide 
exposure and protective endothelial function effects with improved relaxation and less 
arterial contractions than control104. 
In contrast to findings of renal and vascular health improvements, other 
researchers have found significant hypotensive effects on SBP but no changes in 
relaxation responses or ACE activity105.  One study found significant reductions in SBP 
after 8 weeks of ingestion of either of two different milk products: (1) containing 
tripeptides, though there was no effect on aortic relaxation or arterial relaxation 
responses, or (2) containing tripeptides and plant sterols, resulting in enhanced aortic 
relaxation and reduced serum ACE activity in SHR102.  
In summary, there may be additional cardiovascular benefits beyond blood 
pressure lowering that follow treatment with casein-derived peptides.  However, more 
investigation is needed to establish these benefits more firmly.  
 
The potential for other mechanisms for blood pressure reduction 
In support of the widely accepted ACE-inhibiting mechanism for blood pressure 
lowering abilities of dairy-derived peptides, some investigators reported reductions in 
both aldosterone and serum ACE concentrations and reduced angiotensin I to angiotensin 
II contraction ratio in salt-induced hypertensive diabetic mice104.  Additionally, dose-
dependent reductions in blood pressure have been reported with associated findings of 
non-competitive inhibition of ACE71.  In contrast, a study by Fuglsang et al106 examined 
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the ACE-inhibitory effects, as opposed to hypotensive effects, of various peptides using 
different models to indirectly measure the conversion of angiotensin I to angiotensin II, 
or reversion of blood pressure after continuous infusion of angiotensin I, or hydrolysis 
(deactivation) of bradykinin.  No significant effects were observed.  It was suggested that 
the peptides were inactivated upon hydrolysis by serum enzymes.  However, these results 
may support the potential for other blood pressure lowering mechanisms.  Interestingly, 
Ehlers et al21 found that IPP and proline treatments significantly enhanced Ang-(1-7)-
induced relaxation in arterial rings and bradykinin responses.  This finding suggests an 
alternative mechanism for achieving hypotensive effects, that is, through the ACE2-Ang-
(1-7)-Mas axis.  Through this axis, angiotensin I and II are metabolized to Ang(1-7) by 
ACE2, thereby inducing vasodilation in vessels through the Mas receptor, an antagonist 
to the AT1 receptor that promotes pressor responses21.   
Finally, a unique study107 used gene profiling of the aorta of SHR after multiple 
oral doses of lactotripeptides and discovered changes in gene expressions that align with 
in vivo responses to ACE inhibitors, though such changes were much smaller than those 
induced by pharmacological ACE-inhibitory agents.  Although the genes associated with 
the RAAS were not significantly changed, certain genes associated with vascular function 
and blood coagulation were.  For example, connexin and eNOS expressions in the aorta of 
SHR administered the tripeptides significantly increased107.  Increased eNOS expression 
is reported in other studies as well103.  Furthermore, these various gene expression 
changes align with changes observed in previous studies with administration of different 
ACE inhibitors107.   
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Does in vitro ACE inhibition equate to in vivo blood pressure reduction? 
Some studies have found that significant reductions in blood pressure correlate 
with in vitro ACE-inhibitory activity108-110 while others have shown different hypotensive 
effects in vivo of different peptides sharing similar in vitro IC50 values111.  Differences in 
chain length might contribute to such findings, as longer peptides may be more 
susceptible to gastrointestinal proteolysis, but they can also result in peptides with 
considerable antihypertensive effects when absorbed112.  Furthermore, an unobserved 
significant hypotensive effect in vivo may be partly explained by the lack of hydrolysate 
peptides detected in blood, a potential consequence to rapid degradation113.  As supported 
by findings of whey-based studies, it should not be immediately assumed that in vitro 
inhibition will result in in vivo blood pressure reduction, underscoring the importance of 
animal and human based studies. 
 
Studies on safety and toxicity of casein-derived peptides 
As with any bioactive functional food candidate, safety and toxicity studies are 
essential.  Anadón et al114 performed oral toxicity studies on rats that involved a single, 
acute dose of 2000 mg·kg-1 of a powdered casein hydrolysate dissolved in distilled water 
or repeated daily doses of 1000 mg·kg-1 for 4 weeks.  After observing for extended 
periods of time, rats in either study presented with no clinical or behavioral 
abnormalities, no changes in body weight, food or drink intakes, and no statistical 
differences in hematological or clinical parameters were noted.  Furthermore, there was 
no mortality, even with the chronic high dose treatment.  Such findings support the safety 
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of incorporating casein hydrolysate derived from food-grade pepsin114 into a functional 
food. 
 
Antihypertensive effects of casein-derived peptides in vivo: human studies 
Administration of casein-derived peptides 
Casein-derived peptides are the most extensively studied of the food-derived 
ACE-inhibitory peptides in vivo, with strong focus on the two lactotripeptides, IPP and 
VPP.  Often, casein-derived peptides are incorporated into fermented milk 
products88,90,115,115, yogurt-based beverages116-118, fruit juices119, commercial drinks 
Evolus120 or Calpis121, and have even been delivered in a spread89.  Interestingly, a 
number of studies have administered casein hydrolyates containing the lactotripeptides 
IPP and VPP in tablet form122-125.  
 
Chronic dosing of casein peptides 
Although current investigation is insufficient, interest should be paid to potential 
differences in hypotensive effects between oral administrations of isolated 
lactotripeptides and hydrolysates containing these (and other) peptides.  Nonetheless, 
concentrations of IPP and VPP in test products have ranged from 0.72 mg to 10 
mg/100g90,125, with treatment trials ranging from 4 weeks to 24 weeks.  While most 
studies have not examined the potential for dose-response effects, Mizuno et al found that 
both increased doses and prolonged exposure to treatment result in greater reductions in 
systolic and diastolic blood pressures in 131 Japanese subjects in a  randomized single-
blind placebo-controlled study125.  Another study noted that long-term intake (24 weeks) 
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of fermented milk that contained these tripeptides was required to see reductions in blood 
pressure that may have clinical relevance in 89 Finish subjects88.  It is worth noting that 
IPP and VPP concentrations increased midpoint during the 24-week intervention nearly 
five-fold, therefore; it is important to consider that the increased concentrations may have 
also contributed to the observed reductions. 
 In a double-blind, placebo-controlled randomized clinical trial by Ishida et al123, 
48 Japanese subjects with normal or high-normal blood pressures or mild hypertension 
ingested placebo tablets or 20 tablets of 5.0 g/d casein hydrolysate, containing 7.5mg 
VPP and 9.6 mg IPP, estimated to be about 5 times more than the doses determined 
previously by these investigators to be effective for 4 weeks.  It was found that SBP, in 
general, was significantly reduced compared to placebo and after 4 weeks, a reduction of 
8.0 mmHg was observed.  Though not statistically significant (but possibly clinically 
relevant), DBP reduced by almost 4.0 mmHg after 4 weeks compared to the placebo 
group.  Furthermore, SBP of mildly hypertensive subjects reduced significantly, and after 
4 weeks, SBP and DBP reduced by almost 15 mmHg and 7.2 mmHg, respectively.  No 
differences were observed in subjects with high-normal blood pressure.  Importantly, no 
adverse effects associated with ingestion of the tablets and no significant changes in 
blood pressure in normotensive subjects or exaggerated lowering effects were observed.  
This supports the use of such peptides in food products without imposition upon safety 
measures.   
Seppo et al120 found significant reductions in systolic blood pressure among 
hypertensive subjects, both treated and untreated with antihypertensive medications, 
following treatment of 150 mL of the Finnish product, Evolus, for 21 weeks.  There was 
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also a reduction in diastolic blood pressure compared to control groups.  Mean changes in 
blood pressure were about 14 mmHg (SBP) and 8 mmHg (DBP) in subjects not taking 
antihypertensive medications and nearly 13 mmHg (SBP) and 7 mmHg (DBP) among 
those treated with medications.  Importantly, the interaction effects of antihypertensive 
medications and ACE-inhibitory peptide treatments were considered insignificant and no 
adverse effects were reported.  Furthermore, researchers did not discount the possible 
contribution to blood pressure reduction from the higher calcium content in the treatment 
drink compared to the control.  
In summary, chronic doses of casein-derived peptides may reduce blood pressure 
in hypertensive individuals.  Little is known about the effects of treatment resulting from 
a single acute dose; therefore, more research on acute dosing may be warranted.  
 
The use of placebo and ambulatory blood pressure monitoring in casein-
derived peptide blood pressure studies 
There are many challenges when studying the effects of various treatments on 
blood pressure, because it is easily influenced by a variety of external factors.  When 
studying the effects of casein-derived peptides on blood pressure, several researchers 
took certain factors into account.  Many studies assessing the hypotensive effects of 
lactotripeptides have included the use of placebo groups88-90,116-119,121,123,125 to minimize 
the potential for the placebo effect on blood pressure that has reportedly interfered with 
observations of significant effects in some studies115.  Additionally, many studies have 
assessed blood pressure changes primarily through ambulatory blood pressure monitoring 
(ABPM), in effort to minimize confounding variables associated with increased 
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office/clinical blood pressure measurements, often referred to as the white coat 
effect88,90,115,117-119.  ABPM is considered a better, more reliable method for blood 
pressure assessments90.  One study found more than 15 and 10 mmHg increases in SBP 
and DBP, respectively, in office compared to ambulatory baseline measurements90.  
Another found statistically significant reductions in 24-hour ABPM in subjects after 
ingestion of IPP and VPP every day for 10 weeks, with reductions by 7.6 mmHg in SBP 
and 4.1 mm Hg in DBP90.  Some studies examined the hypotensive effects of IPP and 
VPP ingestion on different groups of people, categorized by degree of 
hypertension90,121,123, some of which resulted in significant reductions in SBP in 
individuals with mild hypertension compared to high-normotensive subjects121,123, 
suggesting that treatment may be more effective among individuals with greater degrees 
of hypertension.  More work is needed to investigate blood pressure responses in highly 
hypertensive individuals. 
 
Do lactotripeptides reduce RAAS proteins or ACE activity? 
 A small number of studies of lactotripeptides examined ACE activity and noted 
no changes118, or measured angiotensin I and II concentrations and found no changes121, 
or slight decreases118.  While it has been suggested that the typical doses of tripeptides 
utilized in these studies are too small to have sufficient impact on the RAAS proteins121, 
investigators have considered the possibility of blood pressure lowering effects of 
bioactive peptides exerted by unidentified mechanisms118,119,121. 
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Other vascular improvements as a result of casein peptide treatments 
Similar to animal studies, some researchers have examined other parameters for 
measurement of cardiovascular health benefits of casein-derived peptides in addition to 
arterial blood pressure in humans.  One study investigated the effects on plasma lipid 
profiles following peptide treatment but found no significant changes90,119.  Another study 
considered the effects of tripeptide consumption on arterial stiffness and endothelial 
function in 89 subjects and found significant decreases in the aortic augmentation index 
after 24 weeks of treatment and that this reduction was most pronounced in individuals 
exhibiting metabolic syndrome.  No changes were found in endothelial function but 
serum total cholesterol was also lowered in the treatment group compared to placebo88. 
Interestingly, others examined effects on central arterial systolic blood pressure as 
it might provide a better picture for cardiovascular risk and treatment response and found 
significant reductions of almost 18 mmHg and 22 mmHg at 6 and 9 weeks, respectively.  
These reductions in central SBP resulted sooner and were more profound than those 
observed in brachial SBP.  Finally, reduced arterial stiffness was also observed122.  
 
Other casein-derived hydrolysates 
While the lactotripeptides remain the most extensively studied of the dairy-
derived peptides in human subjects, some researchers investigated the effects of other 
peptides derived from casein.  In a study by Townsend et al124, significant reductions in 
average SBP (by 9.2 mmHg) and  DBP (by 6 mmHg) in 10 subjects of various ethnicities 
(African American, White, and Asian) as recorded by ABPM after ingestion of 6 tablets 
containing a peptide derived from bovine casein, known as C12 (100mg) and alginic acid 
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(1754 mg), a polysaccharide of certain algae.  Reductions of 4.5 and 6.5 for SBP and 
DBP corresponded to intakes of 6 tablets of C12 alone (200 mg), though these reductions 
were not statistically significant.  These findings provide insight to an alternative casein-
derived peptide with potential hypotensive effects.  
 
Fermented milks and yogurts 
Dairy-derived peptides have been produced by fermentative processes in milks 
and yogurts and tested for blood pressure lowering ability.  In a study by Pihlanto et al126, 
two new peptides produced by milk fermentation with Lactobacillus jensenii were 
identified as being primarily responsible for ACE -inhibitory activity in vitro.  However, 
the highest reduction of 10 mmHg in blood pressure observed 90 minutes after 
administration was considered insignificant. Ramchandran et al127 examined the influence 
of probiotics added to yogurts inoculated with starter cultures.  ACE -inhibitory activity 
(in vitro) decreased in samples that were freeze-dried but increased in those added to 
SHR pellet diets.  The authors suggested the possibility that post-fermentative processes 
may influence ACE inhibition. In general, ACE- inhibitory activity was highest in 
samples containing probiotics.  In support of others’ findings, significant blood pressure 
lowering effects were observed in animals who consumed feeds with less potent ACE -
inhibitory activity in vitro and it was noted that high potency in vitro did not positively 
correlate with high antihypertensive effects.  Moreover, in support of others, LDL 
cholesterol-lowering effects were also observed. Seppo et al128 found significant 
reductions in both systolic and diastolic blood pressures, though no changes in heart rate, 
in subjects after consumption of 150ml sour milk fermented by Lb. helveticus LBK- 16 
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H, a strain that remains viable in fermented milk and is well-known to produce the 
hypotensive lactotripeptides IPP and VPP compared to a group consuming an equal 
quantity of a sour milk control.  During a four-week follow-up, blood pressure 
measurements regressed to near baseline values, and were similar to the control group.   
Interestingly, 85-95% ACE inhibition activity was determined in vitro for the fermented 
sour milk and 100% for the synthesized VPP and IPP, both considered high inhibitory 
activities.  Given that the significant reduction in blood pressure was only observed after 
treatment with the sour milk and lactotripeptides, it can be inferred that the attenuation 
was due to the lactotripeptides.  Furthermore, the in vitro inhibitory and in vivo 
hypotensive effects were in agreement, reinforcing the suggestion that casein-derived 
lactotripeptides have the most bioavailability. 
 
Current limitations in studies of casein-derived peptides 
Although the effects of casein-derived peptides, IPP and VPP in particular, are the 
most extensively studied dairy-derived peptides on ACE inhibition, ethnic differences 
and a lack of awareness of the bioavailability of ACE inhibitory peptides remain an 
important limitation to this research.  
Significant effects exerted by these peptides are mostly reported in Asian subjects 
and have not been successfully reproduced in Caucasians117,119.  Suggested reasons 
include the influences of diet, genetics, and baseline blood pressures among different 
ethnic groups, as well as inter-study differences in doses of treatment per kg body 
weight117.  A study by Engberink et al118 found no changes in SBP and DBP  in 135 
Dutch subjects after an 8-week daily consumption of a 200 ml low-fat yogurt drink 
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containing 4.2-5.4 mg IPP and 5.0-5.8 mg VPP produced by fermented milk, enzymatic 
hydrolysis, or chemical synthesis.  Another study on 162 Scottish subjects found no 
significant effects117, but diurnal DBP was significantly reduced in normotensive and 
high-normotensive Mediterranean subjects119.  It appears much more research is needed 
on the effects in various ethnic groups of European, African, and Latin American origins.  
These results suggest that there may well be differences in ACE inhibitory 
potential of these peptides and much more work is needed in order to understand the 
bioavailability of these proteins.  
 
Soy-Derived Bioactive Peptides 
 Soy and soy proteins 
For centuries, soy has been a mainstay of the diet of many Asian 
populations129,130.  Interestingly, although soy foods have been consumed by vegetarians 
and Seventh-day Adventists in the West for about a century, large scale production of 
tofu in the United States only began in the 1970s130.  The introduction of this legume to 
the general population at this time was largely influenced by its adoption by consumers 
with health interests and an ecological mindset, believing that soy was a high quality 
protein source low in saturated fat that was an alternative to animal products, that could 
be produced more efficiently130.  Production and consumption of soy foods increased 
substantially during the 1990s129,130 with the general recognition of soy’s potential health-
promoting benefits resulting from various biological activities of phytochemicals, 
including isoflavones130.  Furthermore, its popularity reached a high in 1999 after 
approval by the Food and Drug Administration of a health claim on labels of foods 
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containing soy protein as protective against coronary heart disease129-131.  The potential 
effects of soy proteins and associated phytoestrogens, specifically the isoflavones, on 
various health conditions beyond hypertension, have been studied and are reviewed 
elsewhere129,130,132.  Increased use in industry is matched by increased waste production, 
particularly following the production of soymilk and tofu.  Waste consists of okara and 
soy whey72.  Interestingly, because of its high protein and sugar content, investigation 
into the use of soy whey as growth medium for probiotics to yield bioactive peptides has 
already been undertaken72. 
Soybean contains about 40% protein consisting primarily of storage proteins 
glycinin and β-conglycinin129,132  that contain all essential amino acids required by 
humans129.  Contributions of these storage proteins to total protein content in soybean 
have been estimated to be between 65 and 80%132 to as much as 90%129.  Results of 
various studies have stimulated investigations into the potential bioactivity of soy 
hydrolysates as shared below. 
 
Antihypertensive effects of soy: In vivo animal studies 
Does in vitro ACE inhibition equate to in vivo blood pressure reduction? 
A meaningful attribute of relatively few studies on soy-derived peptides is the 
inclusion of in vivo experiments preceded by in vitro characterization of ACE-inhibitory 
peptides as they allow for the establishment of relationships between theory and reality, 
that is, between observed potent ACE inhibiting peptides in vitro and consequent 
physiological effects (blood pressure lowering) in vivo.  
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 A study by Kodera et al80 observed dose-dependent responses in the SBP of SHR 
after single oral administrations of 50-1000 mg·kg-1 body weight of soy protein 
hydrolysate produced prior to administration, with significant reductions noted after 
intakes of 100 mg·kg-1  or greater occurring within two hours post-ingestion.  
Additionally, blood pressure attenuation was compared among treatments of hydrolysates 
derived in vitro from casein, soy, milk whey, and wheat gluten protein sources in SHR at 
a dose of 500 mg·kg-1 body weight and found that potency (related as IC50 values) 
mirrored the intensity of the antihypertensive effects for each of the hydrolysates one 
hour post administration, with intensities greatest for casein and soy hydrolysates (in that 
order).  Furthermore, it was observed that while casein and soy effects were immediately 
intense, the SBP-lowering effects of whey and gluten outlasted these, though SBP 
reduction was not significant with whey hydrolysate.  These researchers suggested the 
possibility of a pro-drug-like effect of peptides from the latter sources, in which further 
intestinal hydrolysis might yield more potent, active fragments from inactive, or less 
active, forms.  
Underscoring the value of in vivo studies, Chen et al133 randomized 24 SHR into 
one of three diets containing 5% casein hydrolysate, soy acid-precipitated protein 
hydrolysate, or soy protein isolate for 8 weeks and reported that, although casein and soy 
protein hydrolysates possessed similar IC50 values, their effects were quite different. 
Specifically, the SBP of casein hydrolysate-fed SHR increased during the study while 
significant reductions were observed in the other two soy-fed groups.  It is worth noting 
that IC50 values were lowest in the soy protein forms which exhibited the greatest 
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antihypertensive effects but these values are not necessarily strong predictors when used 
alone.  
Taken together, results from these studies demonstrate the discrepancy between in 
vitro ACE inhibitory potential and in vivo blood pressure lowering abilities, thereby 
confirming the importance of in vivo investigations. 
 
Alternative mechanisms for blood pressure lowering  
Many studies support the mechanism of peptide blood pressure lowering effects 
through ACE inhibition.  A study by Martin et al134 considered the effect on pressor 
responses to angiotensin I with ACE inhibition, postulating that if a soy diet (containing 
soybean oil and unhydrolyzed soy protein) reduced blood pressure through ACE 
inhibition, pressor responses to angiotensin I should be reduced.  To examine this, groups 
included female SHR who underwent bilateral oophorectomy, sham-operated female 
SHR, and male SHR with members of each allocated to a casein- control or soy diet that 
replaced casein protein.  It was found that mean arterial pressures were significantly 
reduced in SHR rats fed the soy diet that were subjected to oophorectomy in comparison 
to casein-fed counterparts.  Dose-response curves comparing angiotensin I with change in 
mean arterial pressure did not reflect theoretical shifts indicative of ACE -inhibitory 
activity.  Furthermore, dose-response curves regarding angiotensin II revealed significant 
but minimal reduction in pressor responsiveness in female SHR fed a soy diet with 
modestly reduced blood pressure.  These researchers concluded that the observed blood 
pressure lowering was not a result of direct ACE inhibition. However, in this study, SHR 
were fed a soy diet that included unmodified protein and soybean oil, not hydrolyzed soy.  
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Therefore, the effects of soy peptides alone on blood pressure and ACE inhibition were 
not assessed.  While results of this study suggest the potential for an alternative 
mechanism for the observed blood pressure reductions, others further support ACE 
inhibition as the primary mechanism.  While results of this study suggest the potential for 
an alternative mechanism for the observed blood pressure reductions, others further 
support ACE inhibition as the primary mechanism.   
In a study by Wu et al135, 20  female SHR were divided into 5 groups that 
included a control without drug or peptide treatments, Captopril-administered at 50 
mg·kg-1 body weight, and groups receiving soy ACE- inhibitory peptides at 100, 500, and 
1000 mg·kg-1 body weight per day that replaced protein in the standard chow diet for 30 
days.  Significant reductions in SBP were found at 6 days into the experiment for SHR 
consuming 500 and 1000 mg·kg-1 soy peptides and 12 days for those consuming the 
lowest dose with SBP reductions from about 193.25 to 155 mmHg at day 30 for this dose, 
suggesting a progressive lowering effect.  Dose-dependent reductions in blood pressure 
were also reported.  Similar to findings in some whey studies, Wu et al noted no change 
in SBP for a group of normotensive rats consuming the highest amount of soy peptide, 
thereby reaffirming the safety in use of bioactive peptides in normotensive individuals.  
Finally, these researchers found no significant changes in aorta and lung ACE activity in 
soy-fed SHR but found increased activity in serum ACE and reduced activity in aorta 
ACE in SHR receiving Captopril for 30 days.  Interestingly, this effect of Captopril has 
been previously reported and, though uncertain, it is suspected that ACE inhibitors may 
induce ACE expression.  Given that serum sodium levels were significantly reduced in 
soy peptide-fed and Captopril-treated groups, a sodium excretion effect is possible. 
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Specifically, angiotensin II promotes sodium retention, and inhibition of ACE results in 
its reduced production and an increase in sodium excretion.  Such findings bring forth the 
additional effects of ACE inhibition beyond reduced vasoconstriction that contribute to 
the antihypertensive effects.  
Yang et al136 divided 40 rats into groups fed diets with varying contributions of 
soy protein hydrolysate (control 0, 1%, 3%, and 5%) for 6 weeks.  Hypertension was 
induced through the use of a nitric oxide synthase inhibitor (NOS-I), L-NAME.  Previous 
studies recognize a relationship between angiotensin II and NO, and that inhibition of 
NOS may induce endothelial dysfunction and hypertension while ACE inhibition may 
result in up-regulation of eNOS, promoting endothelial health, in addition to the 
reduction of angiontensin II136.  As predicted, the SBP and DBP of rats treated with L-
NAME inhibitor increased significantly throughout the experiment.  However, in 
comparison, the blood pressure of rats fed 3% and 5% soy protein hydrolysate diets were 
significantly lower.  Comparatively, significant differences in rats fed 5% soy protein 
hydrolysate included lower ACE activity in the heart, a reduction in heart TNF-α, lower 
MDA levels (malonaldehyde, a marker for oxidative stress) in the heart and aorta, lower 
SOD activity (superoxide dismutase, an enzyme that converts highly reactive superoxide 
radicals into peroxide), and improved vascular remodeling and higher plasma NO.   
Taking these observations into account, it appears that soy protein hydrolysate may limit 
the effects of angiotensin II through its AT1 receptor by inhibiting ACE and increasing 
NO levels and thereby attenuating hypertension and reducing oxidative damage136. 
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Limitations to soy-based studies on blood pressure 
Most soy-based studies on blood pressure do not exclude the potential 
contribution of soy isoflavones to observed health effects.  Consequently, it is 
challenging to establish an exclusive relationship between soy protein and blood pressure, 
even when results support blood pressure reductions.  Furthermore, other studies use 
whole or unmodified soy protein, preventing the determination of a relationship between 
soy-derived peptides and blood pressure.  
A study by Palanissamy et al137 observed elevations in SBP, DBP, mean arterial 
pressure, heart rate, and ACE activity in rats fed a high fructose diet containing 20% 
casein for 60 days but replacement with soy protein attenuated these elevations to near 
normal levels as well as improved insulin sensitivity and renal function.  It was 
determined that the protein source had a profound effect on blood pressure, though other 
factors, including the presence of isoflavones may account for some of these beneficial 
changes137.  However, Yang et al138 found that the SBP of 16 8-week old SHR fed diets 
containing either 0.5% or 1.0% soy protein hydrolysate for 12 weeks was significantly 
lower than SHR fed a standard diet, with differences apparent as early as the second 
(SPH 1.0%) and fourth (SPH 0.5%) weeks of the experiment.  No further changes in 
blood pressure occurred 6 weeks into the experiment, implying that the lowered SBP was 
maintained.  These investigators also examined the ACE activities of aorta, heart, lung, 
and kidney and found that, although aorta ACE activity was highest among all SHR, only 
heart ACE was lower in soy hydrolysate-fed SHR, signifying the possibility of differing 
affinities of peptides for tissues138.  Importantly, plasma electrolyte concentrations were 
unchanged and may suggest that the hypotensive effects of ACE-inhibitory peptides are 
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independent of isoflavones as previous reports suggest a role of isoflavones in the 
reduction of hypertension as a promoter of natriuresis through inhibition of Na-K-Cl co-
transporters138.  This is noteworthy as researchers often attribute effects to isoflavones 
alone.  Finally, Nevala et al139 observed significant reduction in SBP in 8 male SHR fed a 
diet consisting of 20g soy protein with 80 g standard chow for five weeks compared with 
chow-fed control and a 20 g casein-with 80 g chow-fed group.  However, these proteins 
were unhydrolyzed and therefore a relationship between casein-hydrolyzed peptides and 
blood pressure attenuation cannot be made. 
 
Antihypertensive effects of soy: In vivo human studies 
The health benefits of soy are of interest to health professionals and organizations 
as well as the food industry.  However, it appears that the phytoestrogens, especially 
isoflavones, are a central focus.  Incidentally, in a search for human studies on soy 
proteins and blood pressure, nearly all that have been retrieved regard soy diets in 
general, the use of whole (unhydrolyzed) protein, or isoflavones specifically.  Biological 
effects of isoflavones remain controversial and it is conceivable that soy proteins and 
their individual peptides might contribute to observed physiological effects and thus 
warrant further investigation.  
A large longitudinal cohort study of middle-aged and elderly Chinese women was 
conducted by Yang et al140 to determine the association between soy food intake and 
blood pressure.  Inverse relationships between diastolic or systolic blood pressures and 
soy intakes were discovered when measuring blood pressure 2-3 years after reporting 
usual soy food intakes that did not change overtime.  After adjusting for age and BMI, 
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mean systolic and diastolic blood pressures of women with intakes of ≥ 25g soy 
protein/day were 1.9 mmHg and 0.9 mmHg lower, respectively, than mean pressures of 
women consuming < 2.5 grams/day.  Similar relationships were observed between blood 
pressure and isoflavone intake as well.  Furthermore, the blood pressure lowering effect 
of soy intake was most pronounced in elderly women in which for women > 60 years of 
age consumption of  ≥ 25 grams soy protein each day was associated with a reduction by 
4.9 mmHg and 2.2 mmHg in systolic and diastolic blood pressures, respectively, when 
compared to those consuming < 2.5 grams/day.   
A randomized controlled crossover study by Welty et al141 aimed to determine the 
cardiovascular health benefits of supplementation with 0.5 cup of soy nuts containing 25g 
soy protein and 101 mg aglycone isoflavones throughout the day with adherence to a 
TLC diet for 8 weeks.  The subjects consisted of 12 pre-hypertensive and 48 
normotensive women. Supplementation with soy nuts resulted in a significant reduction 
in both systolic and diastolic blood pressures in all pre-hypertensive women and 40 /48 
normotensive women with no changes in BMI or physical activity.  Furthermore, LDL 
cholesterol and apoprotein B were reduced significantly in hypertensive women.  
Although it was expressed that the likely contributor was the isoflavones, one cannot 
discount the potential contribution of peptides derived from digestion and absorption of 
25 grams of soy protein each day, especially when considering hydrolysis of different 
proteins produce different peptides.  
In a double blind crossover clinical trial by Washburn et al142, 51 women were 
randomly assigned to receive one of three treatments: (1) 20 g complex carbohydrate 
supplement without phytoestrogens, 20 g soy protein supplement with 34 mg 
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phytoestrogens (2) to be consumed once per day, or (3) the 20 g soy supplement split in 
half and consumed twice per day, for 6 weeks in duration.  A significant reduction in 
diastolic blood pressure (by an average of 4.9 mmHg) was observed in women 
consuming the soy protein supplement twice per day.   
In a randomized double blind comparative study of consumption of 500 ml of soy 
milk high in isoflavones (63 mg daidzein and 80 mg genistein) and skimmed cow milk 
(no isoflavones) twice daily for 3 months in 40 mild to moderate- hypertensive 
individuals (25 men, 15 women), Rivas et al143 found significant (but moderate) 
reductions in systolic, diastolic, and mean blood pressures in those following the soy milk 
diet compared to cow milk diet controls.  More specifically, reductions by about 18 
mmHg in SBP, 16 mmHg in DBP, and 17 mmHg in mean blood pressure were 
determined after adherence to the soy milk diet compared with reductions by 1.4 mmHg 
in SBP, 4.0 mmHg in DBP, and 3.0 mmHg mean blood pressure found in the control 
group.  Moreover, a strong correlation between urinary genistein excretion and blood 
pressure lowering was observed, though a contributing role from the soy protein is 
possible.  In contrast to previous reports of blood pressure lowering effects of soy protein 
supplementations, a double blind randomized placebo-controlled crossover study by 
Teede et al144, reported that when 41 hypertensive individuals (26 men, 15 
postmenopausal women) were randomized to either a gluten placebo cereal or a soy 
cereal supplement (containing 40 g soy protein and 118 mg isoflavones) for breakfast 
consumption for three months each treatment, supplementation with soy did not result in 
significant changes in 24-hour ambulatory or central blood pressures, in vascular 
compliance, or endothelial function as assessed by brachial artery flow-mediated dilation.  
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Thus, the blood pressure lowering potential of soy-derived peptides remains uncertain.  
More research in humans is warranted. 
  
Conclusion  
While the inhibitory activities of various peptides have been widely studied in 
vitro, information on physiological relevance is lacking.  New technologies and 
sophisticated methods in bioactive peptide production continue to hold promise for the 
discovery of new potent ACE-inhibitory peptides, though they remain unmatched by 
animal, and especially human, studies.  It is evident that in vitro inhibition is an 
insufficient predictor of in vivo antihypertensive effects.  Prevalent inter-individual 
differences and the minimal human data in the literature underscore the need for more 
and larger studies.  Furthermore, there is need for more research into the mechanisms of 
blood pressure lowering effects.  While dairy- and soy-derived bioactive peptides have 
shown blood pressure reductions in animal and human studies, the lack of consistent 
results and the small number of these studies confirm that this area of research is still in 
early stages.  Though more work is needed, the identification and characterization of 
bioactive peptides and their in vitro effects do provide the necessary guidance for 
allowing further advancements to be made.  
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CHAPTER 3: ACE-INHIBITORY EFFECTS OF DAIRY- 
AND SOY-DERIVED PEPTIDES IN PRE-HYPERTENSIVE 
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* Portions of Chapter 3 have been published as a short report: Melissa S. Munn, 
Shalamar Sibley, Richard Brundage, Baraem Ismail, Carrie P. Earthman. “Angiotensin-
converting enzyme inhibitory effects of dairy- and soy-derived peptides in 
prehypertensive overweight men and women.” Functional Foods in Health and Disease, 
2013, Volume 3, Issue 1 (January 27, 2013).  
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Chapter Summary 
Hypertension is considered the most prevalent cardiovascular disorder and a 
significant public health problem.  A functional food that could potentially impede 
progression into a hypertensive state in pre-hypertensive individuals is of significant 
interest to clinicians and consumers.  In vitro and animal studies suggest potential ACE 
inhibitory activity or blood pressure lowering effects of dairy- and soy- derived bioactive 
peptides.  Very few research studies on the effects of whey and soy hydrolyzed proteins 
have been conducted.  The present pilot study tested the acute effects of 20 g doses of 
whey and soy hydrolysates in pre-hypertensive, overweight men and postmenopausal 
women on serum ACE activity and blood pressure.  No differences were observed 
between hydrolyzed proteins and their respective unhydrolyzed counterparts on either 
ACE activity or blood pressure.  These results support a discrepancy between in vitro and 
human based in vivo ACE-inhibitory effects of whey and soy protein hydrolysates, 
underscoring the need for further research to better understand potential explanations for 
these findings.  
 
Introduction 
Considered the most prevalent of cardiovascular disorders, hypertension affects 
nearly 33% of Americans1 and approximately 1 billion people worldwide2, thus, it is a 
significant public health concern3.  The renin angiotensin (aldosterone) system (RAAS) 
plays a significant role in the regulation of blood pressure and involves a cascade of 
events leading to increased blood pressure as a consequence of the conversion of 
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angiotensin I into the potent vasoconstrictor, angiotensin II, facilitated by the angiotensin 
converting enzyme (ACE).  
A first recommendation for the management of hypertension is to alter lifestyle 
habits, especially dietary choices and level of physical activity.  Common dietary 
recommendations include sodium restrictions of less than 1.5 grams (1500 mg) per day 
and the Dietary Approaches to Stop Hypertension (DASH) diet to promote the 
consumption of fresh fruits, vegetables, whole grains, lean meats, and low fat or fat-free 
dairy products.  Such recommendations are frequently accompanied by pharmacological 
medications, including ACE inhibitors.  While these agents help attenuate hypertension, 
they are not without side effects that may render them inconvenient to patients.  
Furthermore, pharmacological interventions can be costly.  A less expensive and more 
convenient alternative is of interest. 
Increased consumer awareness of the relationship between diet and health has 
spurred significant interest in the health-promoting potential of functional foods145.  Of 
these, there is a growing interest in ‘bioactive’ peptides from various protein sources.  
Bioactive peptides are fragments of proteins freed from the parent chain upon hydrolysis 
possessing potential for influence on body functions that may enhance health.  
Researchers have found antihypertensive potential in dairy-derived peptides.  This 
observation has led to efforts to further investigate the potential of these peptides with an 
eye towards developing functional foods that may both attenuate pre-existing 
hypertension and slow or prevent progression into a hypertensive state in pre-
hypertensive individuals.  Immediate benefits of a functional food designed to lower 
blood pressure would include its affordability, availability, and preclusion of the side 
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effects associated with antihypertensive medications.  The majority of antihypertensive 
bioactive peptides have shown ACE-inhibition abilities, largely in vitro.  To the best of 
our knowledge, the most extensively studied food-derived peptides with ACE inhibitory 
potential using human subjects are dairy-derived, particularly the casein-derived 
lactotripeptides, VPP and IPP, with very few studies testing whey hydrolysates.  The only 
human study of whey hydrolysate to date evaluated the effects of chronic consumption on 
blood pressure, but not ACE activity.  There are no published human studies on soy 
hydrolysates on blood pressure or ACE activity.   
Overweight and obesity are associated with hypertension; the therapeutic 
potential of a soy- or milk-derived functional food component to reduce blood pressure in 
this ever-growing population is of substantial interest.  Therefore, we aimed to investigate 
the effects of an acute dose of whey- and soy- derived bioactive peptides on ACE activity 
and blood pressure in pre-hypertensive, overweight men and postmenopausal women. 
 
Methods  
Study Overview  
This was a randomized, single-blind cross-over study in which five treatments 
were compared: 20 grams (g) whey protein hydrolysate (WPH), 20 g whey protein isolate 
(WPI), 20 g soy protein hydrolysate (SPH), 20 g soy protein isolate (SPI), and 20 g 
casein.  A 20 g dose was expected to elicit a biological effect, based on a study reporting 
a significant reduction in blood pressure in humans consuming that dose of WPH for 6 
weeks97.  Each treatment consisted of four (4) equicaloric cookies containing one of the 
treatment proteins (5 g each, 20 g total).   Subjects consumed a controlled diet for the 7-
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day period preceding the first treatment visit, and during a 3-day washout period between 
cross-over treatments.  Figure 2 illustrates the study design. 
 
Subject selection 
Subjects were recruited through the University of Minnesota through Institutional 
Review Board (IRB)-approved campus fliers.   Subjects were eligible to participate if 
they met the following criteria: had a body mass index (BMI) 25 – 34.9 kg/m2; were at 
least 40 years old, had systolic blood pressure values ≥ 90 but ≤ 139 mm Hg and diastolic 
blood pressure values ≤ 90 (taken as the mean of 2 readings),  and,  if a woman, had had 
no menses for at least the past twelve months, was not currently taking any hormone 
replacement therapy medications, or had had a complete hysterectomy at least 12 months 
prior to study participation.   
Individuals were excluded from the study if they were < 40 years of age;  were 
pre-menopausal; were of normal weight (BMI < 25 kg/m2) or Class II and III obese (BMI 
> 35 kg/m2); had pituitary or hypothalamic disease; had congestive heart failure, 
abnormal thyroid function indices, liver failure, renal failure, or diabetes; had an eating 
disorder, clinically significant mental health disease or dementia; were undergoing 
chemo- or radiotherapy treatment for neoplastic disease; were vegetarian or habitually 
consume soy or whey protein products; had soy, nut, or milk allergies; had poor 
dentition; were on diuretics, beta-blockers, angiotensin converting enzyme inhibitors, or 
angiotensin receptor blockers; had menstruated in the last 12 months; had had a 
hysterectomy in the last 12 months; or were on hormone replacement therapy. 
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Individuals who agreed to participate came to the Delaware Clinical Research 
Unit (DCRU) at the University of Minnesota for a screening visit.  During this visit, 
consent was first obtained and then medical history, blood pressure, and anthropometry 
were assessed to determine eligibility.  Once officially enrolled into the study, each 
participant met with a registered dietitian from DCRU Nutrition Services to determine 
energy requirements at an orientation visit.  This information was used to develop a 
controlled diet.  Approximately one week after the orientation visit, subjects were asked 
to adhere to the controlled diet for one week before treatment testing.  At the end of the 
week, study participants underwent testing at five visits to the DCRU, separated by a 
three-day washout period to evaluate responses to the different treatment arms.  These 
participants adhered to the controlled diet for the duration of the study.  The study 
protocol was reviewed and approved by the IRB and the Clinical and Translational 
Science Institute at the University of Minnesota. 
 
Testing Visits 
Subjects arrived to the DCRU by 0700 the day of their testing visit (for each of 
the five visits) following a fast from 1900 the day before and were asked to void their 
bladders and to dress in light weight clothes for weight measurements.  Subjects were 
then instructed to lie supine in a bed with one pillow supporting the head for 30 minutes 
before the baseline blood draw and throughout the entire testing period.  The head of bed 
could be elevated at most up to 30 degrees plus one pillow.  The nursing staff placed a 
peripheral IV line for blood draws in the non-dominant arm and initiated Dinamap blood 
pressure readings that were monitored at the baseline blood draw and at each blood 
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sampling time point.  After an initial thirty minute rest, blood was drawn for baseline 
measures of ACE activity and blood pressure was assessed.   Participants then consumed 
the protein cookies based upon randomized assignment to one of five treatment arms:  
WPH; WPI; SPH; SPI; or casein.  During consumption of the treatment, participants were 
encouraged to consume approximately 120 ml of water without ice.  Consumption of the 
treatment was completed over a 15 minute period (± 5 minutes), at the end of which 
began the follow-up period (denoted as Time 0).  Blood sampling time points occurred in 
thirty minute intervals from Time 0:  +30, +60, +90, +120, +150, and +180 minutes.   
These sampling points were determined from a preliminary pilot study (unpublished) in 
which nine subjects received one of the five treatments (20 g of casein, SPH, SPI, WPH, 
or WPI) and blood was collected at fifteen and thirty minute intervals over a five hour 
period.  Data from this study suggested that maximal ACE activity suppression could be 
captured between 60-180 minutes and thus a 180 minute follow-up period was utilized in 
the cross-over study.  
 
Anthropometric Assessment 
Subjects were measured for height (cm) and weight (kg) following standardized 
procedures.  Height was measured by a wall-mounted stadiometer to the nearest 0.1 cm. 
Body weight was measured on a stand-on digital scale to the nearest 0.1 kg.  Body mass 
index (BMI) was calculated using the formula: BMI = kg/m2.   
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Controlled Diet 
The controlled diet was designed by the DCRU Nutrition Services to meet each 
individual’s determined energy needs, to be whey-, soy-, and dairy-free, and to provide 1 
gram of sodium per 1,000 calories and 1.5 grams of potassium per 1,000 calories daily.  
A Registered Dietitian determined caloric content for each individual’s diet estimated by 
calculating resting metabolic rate using the Harris Benedict Equation146 and then 
multiplying that by the subject’s estimated physical activity factor.  
During the study period, subjects were provided all their food by the DCRU 
metabolic kitchen; they picked up their food on a daily basis throughout the study period.  
They were asked to adhere to the controlled diet and to report off-plan intake to Study 
Personnel and on food records.  At the orientation visit, subjects were instructed by Study 
Personnel on how to keep accurate dietary records and were provided with simple forms 
for daily record-keeping.  These diet records were reviewed by Study Personnel at testing 
visits in an effort to assess subject compliance.  Additionally, subjects were required to 
return uneaten food to the DCRU when picking up the following day’s meals as an 
additional effort to track subject compliance.    
 
Protein Treatments 
Production of hydrolysates and in vitro ACE inhibition   
Davisco Foods International, Inc. (Eden Prairie, MN) provided the whey protein 
isolate (BiPro) and the whey protein hydrolysate (Biozate 1) to be incorporated into the 
nutritional cookies for this study.  Defatted and minimally heated soy flour samples were 
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provided by Archer Daniels Midland Company (Decatur, IL) for the preparation of soy 
protein isolate (SPI).  Soy protein hydrolysate (SPH) was produced by selective 
hydrolysis with papain to β-conglycinin –hydrolyzed SPI as described147.  In vitro ACE 
inhibitory activity measurements of SPH and WPH were performed in triplicate using N-
[3-(2-Furyl)acryloyl]- L -phenylalanyl-glycyl-glycine (FAPGG) as substrate147. 
 
Preparation of the cookies    
Cookies were prepared with the goal of achieving a palatable dose of 20 g of 
protein incorporated into four cookies.  Trials for cookie preparation were repeated 
several times by the same student who prepared them at each testing visit for each subject 
to ensure consistency in preparation methods and procedures.  Weight was measured 
using a digital scale and small measures of liquid ingredients were controlled using 
transfer pipettes.  The measured amount of each ingredient was scaled up to account for 
loss during preparation.  The four cookies were baked together in a conventional oven at 
350 degrees Fahrenheit for 7 minutes.  Furthermore, the treatment cookies were 
equicaloric, varying only by the type of protein incorporated.  (See Table 1 for a detailed 
description of the formulation of the cookies.) 
To guarantee freshness, cookie preparation began by 0530 the morning of each 
testing visit; they were delivered by the student to the DCRU by 0700.  
 
Plasma ACE Activity Assay 
At each time point, 5 ml of blood was collected into serum separator tubes (SST).  
Each of these samples was allowed to clot and held at room temperature.  Samples were 
 72 
batched cold spun at 3000 rpm for 10 minutes after the final sample clotted.  Then, 1ml 
of serum was aliquotted into cryogenic vials in duplicate, flash frozen with dry ice and 
alcohol, and stored in an ultracold freezer (-80 degrees F) before being shipped on dry ice  
to ARUP Laboratories (Salt Lake City, Utah) to be assayed for ACE activity.   
 ACE activity was measured using the synthetic substrate FAPGG (N-[3-(2-
furylacryoyl)]-L-phenylalanine-glycyl-glycine).  The ACE enzyme hydrolyzes FAPGG 
to FAP (furylacryyloylphenylalanine and glycylglycine).  Its hydrolysis results in a 
decrease in absorbance at 340 nm as measured by a spectrophotometer. ACE activity is 
expressed in units per liter (U/L). 
 
Statistical Analysis  
Area under the curve (AUC) was calculated for each subject and for each 
treatment for both ACE activity and systolic blood pressure from baseline to 180 minutes 
post consumption of cookie treatments.  From these, mean AUCs were calculated for 
each treatment.  Our primary interest was to compare whey and soy hydrolysates (SPH 
and WPH) with respective isolate counterparts (SPI and WPI) for both ACE activity and 
systolic blood pressure.  However, because it was also possible (although not likely) that 
in vivo digestion of the whey and soy protein isolates as well as the casein could 
potentially have yielded ACE-inhibitory bioactive peptides, we evaluated the differences 
across all treatments in ACE activity and blood pressure using repeated measures 
ANOVA with post-hoc comparisons.  AUC data from 0-180 minutes and from 60-180 
minutes were evaluated, as we observed in the pilot study that ACE suppression appeared 
to be maximally captured within this narrowed window of time.  A significance level of 
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0.05 was considered significant.  Repeated Measures ANOVA was performed using 
GraphPad InStat version 3.10 for Windows (GraphPad Software, San Diego California 
USA, www.graphpad.com). 
 
Results 
The in vitro ACE inhibitory activity of the SPH and WPH samples were evaluated 
in the laboratory of Dr. Baraem Ismail.  The ACE inhibitory activity was expressed as 
IC50 values (the amount of the inhibitor required to reduce enzyme activity by 50% of its 
original activity).  SPH showed comparable, though slightly greater ACE inhibitory 
activity compared to WPH, with IC50 of 0.177 mg SPH protein/mL compared to 0.200 mg 
WPH protein/mL147. 
Importantly, throughout the study period, no adverse events were reported.  
Subjects tolerated the treatment protein cookies fairly well; however, there were several 
logistical challenges, including the long period of time during which subjects were asked 
to lie in the supine position, even while consuming the treatment cookies.  In addition, 
staffing changes at the metabolic kitchen, and the early morning schedule for making the 
treatment cookies with limited staffing in the laboratory of Dr. Ismail also presented 
some difficulties.  Due to these and other challenges, the decision was made to conduct 
an interim analysis of ACE activity and blood pressure data from the first four subjects 
who completed the study protocol before proceeding with additional subject recruitment.  
Based on the lack of any significant differences between the treatment proteins on ACE 
activity and blood pressure, subject recruitment was halted.  Data from these first 4 
subjects who completed the entire study protocol are presented here.   
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The subjects were Caucasian men and postmenopausal women (2 F, 2 M) with a 
mean ± SD age of 58±1.3 years and a BMI of 28±.7 kg/m2.  Mean systolic and diastolic 
blood pressures were 118±7 mmHg and 81±6 mmHg, respectively.  Subject compliance 
to the controlled diet was quite good, as reflected by daily food records and weigh back 
information for each meal, and urinary sodium and potassium intake.  Table 2 presents 
dietary intake, serum, and urinary sodium and potassium data for each study visit.  The 
controlled diet was well tolerated and subjects conveyed a strong liking for the entrees 
and snacks provided.  Tables 3 and 4 present the ACE activity and systolic blood pressure 
AUC data, respectively, for each subject and each treatment.  No differences in ACE 
activity were found among the mean AUCs of the five treatments between 60-180 
minutes (p = 0.97) or from 0-180 minutes (p = 0.76) post treatment.  The power of the 
test for the comparison of treatments by repeated measures ANOVA was <10%, 
suggesting there is insufficient data to show that a statistically significant difference 
exists between the treatments.  Mean ACE activity over time by treatment is graphically 
represented in Figure 3.  
When considering the effects on systolic blood pressure, no statistically 
significant difference was found among the five treatment groups from 60-180 minutes (p 
= 0.52) or from 0-180 minutes (P = 0.72) post-treatment.  A graphical representation of 
mean systolic blood pressure for each treatment is presented in Figure 4.  
 
Discussion  
An acute dose of 20 grams of hydrolyzed whey or soy protein did not result in a 
reduction in serum ACE activity or arterial systolic blood pressure in overweight mildly 
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pre-hypertensive men and postmenopausal women within 180 minutes post treatment 
consumption despite apparent in vitro ACE inhibitory activity.  It is probable that the 
amount of ACE inhibitory peptides found in a 20 g dose of either SPH or WPH was 
insufficient to achieve notable reductions in either ACE activity or blood pressure as only 
a fraction of the peptides may possess ACE inhibitory activity.  It is also possible that 
chronic intake of bioactive peptides is required to achieve pronounced reductions.  
However, we found only two human-based studies on hydrolyzed whey protein and 
blood pressure.  One of these, Lee et al148, found no differences in blood pressure 
following daily ingestion of 125 ml of a milk drink supplemented with whey peptides for 
12 weeks148.  The other reported significant reductions in systolic and diastolic blood 
pressures following daily consumption of a 20 g dose of hydrolyzed whey protein for 6 
weeks; however, the paper was later retracted due to the discovery that results were based 
on falsified data98.  Thus, in essence there have been no valid reports of whey protein 
demonstrating blood pressure or ACE inhibitory effects in humans.  In addition, the 
blood pressure lowering potential of hydrolyzed soy proteins in humans is completely 
unknown.  
Interestingly, Lee et al148 also confirmed ACE inhibitory potential in vitro of a 
whey peptide powder prior to its administration to subjects.  The clear discrepancy 
between the apparent in vitro ACE inhibition and the lack of in vivo lowering of ACE 
activity and blood pressure underscores the need for more human-based studies.  Whey 
and soy hydrolysates have been studied for survivability to digestion using pepsin, 
trypsin, and chymotrypsin treatments as well as elaborate in vitro models that simulate in 
vivo digestive processes and have largely been found to remain intact or undergo further 
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hydrolysis, resulting in the release in smaller more potent inhibitors with lower IC50 
values33,35,38,43,57,62-64,67,76-79.  Although di- and tripeptides and some other small 
oligopeptides are more easily absorbed intact, most are further hydrolyzed by the various 
luminal, brush border, and cytosolic peptidases of enterocytes into free amino acids prior 
to entry into systemic circulation.  A short half-life (minutes) presents an additional 
barrier to optimal bioavailability that results from hydrolysis by peptidases in plasma and 
vascular endothelium149.  A bioavailability of < 0.1% in pigs and peak concentrations in 
picomolar amounts in humans administered two well-known tripeptides, isoleucine-
proline-proline (IPP) and valine-proline-proline (VPP), both reported to be absorbed 
intact, illustrates these inherent challenges149.  Data on human plasma concentrations of 
whey and soy-derived peptides is severely lacking, though it provides important 
information to ascertain in vivo effects. 
Undoubtedly, the most studied mechanism behind hypotensive properties of 
peptides has been ACE inhibition. However, both ex vivo and in vivo studies in 
spontaneously hypertensive rat models have suggested the potential for other mechanisms 
in reducing blood pressure including interactions with opioid receptors, possibly 
increasing vasorelaxation95,96. 
 It should also be considered that other studies have found discrepancies between 
in vitro ACE inhibition and consequent in vivo blood pressure effects upon peptide 
administration in spontaneously hypertensive rats.  Specifically, Murakami et al95 noted 
that ovalbumin-derived peptides achieved the highest % ACE inhibition (signifying 
potent ACE inhibitory potential) but exerted the weakest antihypertensive effects.  In 
contrast, high IC50 values corresponded to certain peptide fractions of whey protein 
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(suggesting weak inhibition) though these peptides reduced blood pressure by 19 mmHg 
at 6 hours and nearly 22 mmHg at 8 hours post administration.  Results of various in vitro 
studies subjecting peptides to digestive proteases suggest that certain peptides may not 
survive digestive processes as they are susceptible to further hydrolysis (especially if 
chain lengths are >7-9 amino acids) potentially resulting in loss of activity57,64.  However, 
other studies have found peptides that either maintained ACE inhibitory potential post 
treatment with digestive enzymes33,38,57,62-64,67,77,78 or peptides with enhanced ACE 
inhibitory potential as a result of further hydrolysis, likely producing smaller, more potent 
peptides than may be absorbed intact43,57,64,77.  
The delivery of protein treatments in whey studies included liquid forms such as 
water or milk beverages97,148.  Studies on soy protein have included whole protein: soy 
nuts141, soy milk143, soy protein supplement142, or soy cereal supplementation144 and the 
potential contribution of soy isoflavones were recognized.  Thus, studies on hydrolyzed 
soy protein and ACE inhibition and blood pressure lowering effects are needed.  The 
insolubility of soy protein hydrolysate in liquid and the desire to deliver 20 g protein 
treatments in a palatable form influenced the decision for the unique delivery form of a 
cookie in our study.  Nonetheless, the possibility of thermal or pH instability during the 
baking process may influence the bioactivity or digestive survivability of the soy and 
whey peptides as little is known about this147.  It is possible that heat and alkaline 
conditions may alter the quaternary and tertiary structures of peptides (‘protein 
unfolding’ or denaturation), ultimately exposing other active sites for additional 
enzymatic cleavage or rendering peptides inactive.  We tested ACE inhibition of SPH 
post subjection to heat treatments of either 120 °C or 175 °C for 10 or 15 minutes, similar 
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to what would be expected during cookie baking. Experimental methods and procedures 
are discussed elsewhere147.  Results confirmed thermal stability as ACE inhibition (IC50 
values) did not change between heat treatments and did not differ from an unheated 147.  
However, we did not test for stability to increased pH (as might be expected with the 
addition of sodium bicarbonate (baking soda) and baking powder).  Furthermore, it is 
possible that pH and heat may exert a combined effect that jeopardizes peptide 
bioactivity, though little is known about this.  Finally, though little is known, inherent 
reactions that occur in heat conditions between proteins and reducing sugars, collectively 
termed non-enzymatic browning reactions, such as the Maillard Reaction, may influence 
bioactivity147.  
 There were several strengths to this study.  We employed a randomized cross-
over design, allowing that each subject served as his or her own control to ascertain the 
effects of each treatment.  Unlike other studies, we examined the hypotensive potential of 
two protein sources, hydrolyzed whey and soy, and compared them to unhydrolyzed 
counterparts and a reference, unhydrolyzed, casein protein.  Examination of bioactivity 
was not limited to blood pressure data, as we expanded our endpoints to include ACE 
activity.  If a hypotensive response to either or both hydrolyzed proteins was observed, 
changes in ACE activity would have provided important information.  A mild activation 
of the RAAS is important when studying ACE inhibition. Reduced sodium intake may 
stimulate plasma renin activity and increase aldosterone levels150,151 and consistent 
sodium and potassium intake prevented day-to-day fluctuations that could impose 
unwanted variability within subject data; therefore, subjects adhered to a sodium and 
potassium controlled diet that was dairy- and soy- free.   Additionally, compliance was 
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strongly reinforced with the use of diet records, the required return of uneaten food, daily 
pickup of meals, and urine analysis.  Finally, subjects were asked to be consistent in 
choice of activity to pass the time at each visit.  For example, if a subject rested with her 
eyes closed at the first visit, she was asked to do this at each visit and for the duration of 
that visit.  Consistency in activity also minimized unwanted variability. 
Our study was not without limitations.  This was not a dose-response study.  We 
only tested the effects of a 20 g dose of protein and recognize that this amount could be 
insufficient.  More information could have been obtained examining the effects of 
various doses to determine a minimum amount of protein treatment required to achieve 
an observable response.  We also did not measure other RAAS proteins, such as serum 
angiotenin II, which would have provided vital information to support or negate the 
proposition of ACE inhibition as the primary mechanism for blood pressure lowering 
effects.  Finally, we developed a cookie for treatment delivery as a solution to the 
insolubility of the soy protein isolate and hydrolysate, which made a liquid form 
unfeasible.  Given the potential susceptibility of peptides to denaturation and further 
enzymatic hydrolysis as consequences to pH change and the Maillard Reaction, a baked 
cookie may not have been the most ideal delivery system.  Further work should be done 
to devise and evaluate optimal ways to deliver these bioactive peptides to humans.  
 
Conclusion 
In our study, reduced blood pressure and ACE activity did not occur following an 
acute dose of 20 g of either soy or whey protein hydrolysate.  The discrepancy between 
the positive observations of ACE-inhibitory activity by soy and whey protein 
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hydrolysates in vitro, and the lack of in vivo evidence of ACE inhibition or blood 
pressure lowering in human studies underscores the need for more research, particularly 
to determine peptide bioavailability for optimal dosing to elicit in vivo effects.  There is 
much interest in the production of a functional food for the attenuation of existing 
hypertension and, perhaps more importantly, for the delayed or prevented progression 
into a hypertensive state in those with prehypertension.  Such a preventative approach 
could have important public health implications, especially when considering the high 
rates of obesity.  However, the potential efficacy of these whey and soy protein-derived 
bioactive peptides must be established through rigorous human trials before functional 
foods containing these peptides become available to consumers.  
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Figure 2.  A sample schedule 
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Each subject received the five treatments in a randomized order, each at a different visit: soy 
protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate (WPI), whey protein 
hydrolysate (WPH), casein.  A controlled diet was followed throughout the study, beginning one 
week before testing; treatments were separated by 3-day washout periods.          
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Table 1.  Protein Treatment Cookie Ingredients 
 
Ingredient  Amount (g)*  
Protein**  24.83  
Butter  21.59  
Starch  21.59  
Brown sugar  16.198  
Splenda  1.94  
Baking soda  0.539  
Baking powder  0.269  
Almond flavor  0.2159  
Vanilla flavor  2.159  
Walnut oil  2.159  
Water  18.358  
Chocolate chips  15.118  
Total⁺ per cookie⁺⁺ 125⁺  28.94⁺⁺ 
*Amounts have been scaled up to account for losses during preparation                                                                                                
** Proteins: casein, soy protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate 
(WPI), or whey protein hydrolysate (WPH) 
⁺Total weight of dough before dividing into 4 cookies; ⁺⁺Weight of each of the 4 cookies  
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Table 2.  Dietary, Serum and Urinary Sodium and Potassium for Each Testing Visit 
ID Testing 
Visit 
Na+ 
Intake 
(mg)* 
Serum 
Na+ 
(mmol/L)  
Urinary 
Na+ 
(mmol/L) 
K+ 
Intake 
(mg)* 
Serum K+ 
(mmol/L) 
Urinary 
K+ 
(mmol/L)  
85001 Visit 1 1992 140  80 3099 4.2  64 
Visit 2 1992 139 71 3099 4.2 66 
Visit 3 1992 139 72 3099 4.0 65 
Visit 4 1992 141 93 3099 4.7 71 
Visit 5 1992 140 82 3099 3.9 65 
        
85004 Visit 1 2600 140 48 3125 3.8 19 
Visit 2 2572 140 N/A** 2733 4.0 N/A** 
Visit 3 2736 139 28 3320 3.9 15 
Visit 4 2129 140 36 2444 4.0 24 
Visit 5 2301 140 56 2907 3.7 33 
        
85005 Visit 1 2963 140 41 3895 3.9 34 
Visit 2 2963 140 28 3895 3.8 15 
Visit 3 2963 141 54 3895 3.7 26 
Visit 4 2963 139 22 3895 4.0 31 
Visit 5 2963 140 18 3895 3.6 31 
        
85007 Visit 1 2125 141 N/A** 3134 3.8 N/A** 
Visit 2 2125 139 22 3134 3.7 32 
Visit 3 2125 140 32 3134 3.7 62 
Visit 4 2125 142 31 3134 4.0 21 
Visit 5 2125 141 31 3134 3.7 29 
*Dietary intakes of potassium and sodium were determined from weigh-back information taken 
from one day prior to the testing visit. 
** Urine specimen not collected/analyzed. 
 
Subjects 85001, 85005, and 85007 consumed everything provided at each meal. 
Therefore, sodium and potassium intake values did not vary for these individuals.  
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Table 3.  Angiotensin Converting Enzyme (ACE) Area-Under-the-Curve (AUC) by 
Treatment 
 
 
Treatment 
 
Subject ID 
 
 
AUC 60-180 min 
 
AUC 0-180 min 
 
 
 
Casein 
85001 3825 6150 
85004 5445 7980 
85005 7110 10785 
85007 4170 6270 
Mean 5138 7796 
SD 1488 2161 
 
 
 
SPI 
85001 3405 4845 
85004 4845 7290 
85005 6892.5 10485 
85007 4575 6900 
Mean 4958 7429 
SD 1620 2272 
 
 
 
SPH 
85001 3405 4845 
85004 4845 7290 
85005 6892.5 10485 
85007 4680 7035 
Mean 4956 7414 
SD 1443 2323 
 
 
 
WPI 
85001 3885.00 5475.00 
85004 5490.00 8310.00 
85005 6630.00 10335.00 
85007 4080.00 6180.00 
Mean 5021.250 7575 
SD 1289 2200 
 
 
 
 
WPH 
85001 4410.00 6675.00 
85004 4545.00 7155.00 
85005 6930.00 10965.00 
85007 4050.00 6495.00 
Mean 4984 7823 
SD 1314 2113 
Abbreviations:  Soy protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate 
(WPI), whey protein hydrolysate (WPH), casein 
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Table 4.  Summary of Systolic Blood Pressure Area-Under-the-Curve (AUC) by 
Treatment 
 
 
Treatment 
 
Subject ID 
 
 
AUC 60-180 min 
 
 
AUC 0-180 min 
 
 
Casein 
85001 11280 16800 
85004 15360 22830 
85005 12045 18135 
85007 14580 21195 
Mean 13316 19740 
SD 1961 2762 
 
 
SPI 
 
85001 11190 16860 
85004 14790 22245 
85005 13125 20250 
85007 13320 20085 
Mean 13106 19860 
SD 1478 2228 
 
 
 
SPH 
 
 
 
 
85001 11625 17205 
85004 16140 24480 
85005 12810 19020 
85007 13275 19875 
Mean 13463 20145 
SD 1915 3097 
 
 
 
WPI 
 
85001 11055 16770 
85004 14715 22005 
85005 12885 19230 
85007 13320 19740 
Mean 12994 19436 
SD 1510 2148 
 
 
 
WPH 
 
85001 10890 16470 
85004 15495 23850 
85005 11730 17430 
85007 13260 19680 
Mean 12844 19358 
SD 2022 3283 
Abbreviations:  Soy protein isolate (SPI), soy protein hydrolysate (SPH), whey protein isolate 
(WPI), whey protein hydrolysate (WPH), casein 
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Figure 3.  Mean Angiotensin Converting Enzyme (ACE) Activity vs Time by Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
 
Figure 4. Mean Systolic Blood Pressure (SBP) vs Time by Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
 
 
 
 
 
 
 
 
CHAPTER 4: CONCLUSIONS 
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Hypertension, the silent killer, is considered the most prevalent of cardiovascular 
disorders and is projected to affect almost a third of the world population by 2025.  It is 
recognized as a leading cause of kidney failure and poses significant risks for myocardial 
infarction, heart failure, and stroke.  Essential hypertension was once accepted as a 
disorder primarily in older adults; however, it now spans across all age groups, affecting 
children and adolescents parallel to obesity.  This is a significant concern for children as 
childhood blood pressure is a predictor of blood pressure in adulthood.  Though certain 
risk factors cannot be modified, a heart healthy diet and various lifestyle factors can 
greatly reduce one’s risk.  Prehypertension is an important risk factor for hypertension 
and is a focus for preventative approaches. 
The RAAS is primarily responsible for blood pressure regulation and thus is a 
target system for pharmacological interventions.  Although blood pressure lowering 
medications work well, they can be costly and impose unwanted side effects.  A 
significant amount of money is spent in the US on healthcare related to hypertension.  
Interest in a functional food that can impede progression from prehypertension to a 
hypertensive state is strong.  Many in vitro studies have found ACE inhibitory potential 
in peptides derived from dairy and soy proteins.  Much emphasis has been placed on 
production and sequencing of the peptides.  While important information is obtained in 
this work, results from in vivo studies determine the ultimate worth of the peptides.  
Though the existing body of research on bioactive peptides with ACE inhibitory potential 
is compelling to many scientists in academic institutions and the food industry alike, 
current research is highly deficient in the most relevant area of all, human-based work.  It 
is this deficiency which ultimately keeps this field in its infancy, regardless of in vitro 
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advancements.  Even so, two well-known products already exist in Japan (Calpis) and 
Finland (Evolus) containing the best studied casein-derived tripeptides, IPP and VPP.  
Interestingly, results of Japanese and Finnish studies have largely not been reproducible 
in other ethnic groups. 
We conducted a randomized cross-over controlled single blind study to test the 
effects of 20 g doses of whey and soy hydrolysates on blood pressure and ACE activity 
over the course of 180 minutes post treatment consumption, using unhydrolyzed soy and 
whey counterparts as respective controls.  An interim analysis on four subjects revealed 
no differences in ACE activity among the five treatment groups and no differences 
between hydrolyzed and unhydrolyzed pairs.  To the best of our knowledge, after 
searching eleven databases, only two studies tested the effects of whey hydrolysates on 
humans and very little has been studied on hydrolyzed soy protein.  Given this, much 
more work is needed.  
The idea of incorporating peptides derived from dairy or soy into a functional 
food that can be consumed daily by individuals at risk for developing hypertension is 
intriguing.  Though very few human studies exist, animal based studies do support the 
potential for blood pressure lowering effects exerted by peptides.  More information is 
vitally needed regarding bioavailability and efficacy of food-derived ACE inhibitory 
peptides to positively impact blood pressure in humans.   With additional data on these 
important questions, it is quite possible that functional foods based on dairy and soy-
derived peptides may be welcomed by the food industry, academic scientists and 
consumers as a non-pharmacologic approach to reducing hypertension.  The 1970 
discovery of peptides in viper snake venom possessing the ability to inhibit ACE signifies 
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an important milestone for public health and the therapeutic preventative potential of the 
more recently identified food-derived ACE inhibitory peptides may one day result in 
another. 
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